Introduction {#s1}
============

Hematopoiesis is an essential biological process leading to the genesis of all blood lineages throughout life. Currently, producing full-potential hematopoietic stem cells (HSCs) in vitro remains a challenge ([@bib60]), in particular for regenerative purposes. This points to the relevance of reinforcing the fundamental knowledge of the process as it occurs in vivo.

HSCs with long-term replenishment potential are formed in the embryo according to a genetic program highly conserved between vertebrate species ([@bib9]; [@bib10]; [@bib24]). HSCs emerge during the so-called definitive wave of hematopoiesis, from vascular components, in particular the ventral floor of the dorsal aorta, in the aorta-gonad mesonephros (AGM) region as well as from the umbilical and vitelline arteries in mammals.

The zebrafish has proven to be an extremely valuable model for studying the developmental aspects of hematopoiesis ([@bib12]); the combination of cell tracing and live-imaging have notably allowed to trace the migration of definitive hematopoietic stem and progenitor cells (HSPCs) to successive hematopoietic organs ([@bib25]; [@bib30]; [@bib44]). Real-time in vivo imaging also established unambiguously the aortic origin of definitive HSPCs, that were visualized emerging as single cells directly from the hemogenic endothelium in the floor of the dorsal aorta ([@bib5]; [@bib29]). This very unique type of cell emergence, called the endothelial-to-hematopoietic transition (EHT), is characterized by an unusual bending of the cell that increases while the emergence is progressing, and so until the exit from the vascular wall ([@bib29]). The process was also described ex vivo in slices of mouse embryos, although at a lower resolution ([@bib7]). An apparent difference between zebrafish and mouse is the direction of the emergence, with HSPCs extruding into the sub-aortic space in the former and into the aortic lumen in the latter (where they initiate the so-called intra-aortic clusters). The reasons for such a difference are currently unknown and may relate to different biophysical constraints of the aortic and sub-aortic environments in either species.

The vascular and aortic systems have very unique characteristics ([@bib2]). They are constituted by extremely flat endothelial cells with luminal/apical and basal membranes having virtually equal surfaces (a so-called squamous epithelium) and organized around a lumen filled with blood cells and fluid, and exposed to high mechanical loading, including shear stress exerted on the surface of endothelial cells as well as circumferential wall stress ([@bib39]). Blood flow also appears to regulate endothelial cell fates in development ([@bib13]) and, in regard to hematopoiesis, to have an influence on the expression of key transcription factors such as Runx1, the transcription factor essential for hematopoiesis, both in mouse embryonic stem cells ([@bib1]) and in the zebrafish ([@bib47]). Hence, comprehending the fundamental mechanisms of HSC emergence requires taking into account the peculiarities of the vascular environment and the mechanical constraints.

The EHT allows single live cells to leave a squamous epithelium without perturbing its integrity. Most other cell extrusion processes that have been described concern thick, columnar/cuboidal epithelia, and among them, only the epithelial mesenchymal transition (EMT, \[[@bib35]; [@bib46]\]) gives rise to live wandering cells endowed with a new potential, as the EHT does. Hence, in order to specify further the peculiarities of the EHT and to be able to establish comparisons with the other cell extrusion processes described so far, we delved deeper into the process, taking the vascular environment into account. To do so, we developed a novel algorithm allowing the deployment of the aortic wall into high-resolution 2D-cartographies and 2D-time-lapse sequences. We also addressed the influence of blood flow on the EHT morphodynamics by abrogating heart beating. This led us to uncover some of the key and unique features of the EHT (and to draw a comprehensive model of its main steps) and identify the contribution of some of the essential molecular components involved in the morphological changes accompanying the emergence. Further, our analysis brought insight into the dynamic interplay between cells undergoing EHT and adjoining endothelial cells and pointed to the essential role of blood flow in HSCs emergence.

Results {#s2}
=======

EHT dynamics at high spatio-temporal resolution {#s2-1}
-----------------------------------------------

In order to unravel the critical biomechanical features of the EHT, we performed confocal live-imaging at high spatio-temporal resolution. In comparison to previous work ([@bib29]), we improved the spatial resolution of our time-lapse (TL) sequences by reducing the distance between the sequential optical planes (0.43 μm instead of 2 or 0.60 μm) and improved the temporal resolution by reducing the 5 min intervals between Z-stacks acquisitions down to 2 min when performing spinning-disk confocal imaging. We imaged the dorsal aorta (DA) of transgenic zebrafish embryos ([Figure 1A](#fig1){ref-type="fig"}), starting at 48 hpf (corresponding to the timing at which the EHT process is culminating, see [@bib29]), until 72 hpf. We noticed that the angles of emergence of EHT undergoing cells (hereafter designated as \'EHT cells\') varied between approximately 0--45° from the dorso-ventral axis of the DA and 0--45° from its antero-posterior (A-P) axis. In general, the most valuable information was obtained from cells for which the two most distant poles were parallel to the A-P axis ([Figure 1B](#fig1){ref-type="fig"}). We initiated the study using *Tg*(*kdrl:Ras-mCherry; kdrl:eGFP)* fish so as to visualize cellular membranes as well as the cytoplasmic volume. As previously described ([@bib29]), the morphological criterion allowing unambiguous identification of cells having initiated the EHT is their cup-shaped morphology, with bending toward the sub-aortic space. Hence, many of our TL sequences were initiated at this stage, increasing chances to image completion of the process and minimizing the risk of phototoxicity (see [Figure 1C](#fig1){ref-type="fig"} for a 3D-rendering view, and [Figure 1---video 1](#fig1video1){ref-type="video"}, [Figure 1---video 2](#fig1video2){ref-type="video"}). Ras-mCherry allowed visualizing the luminal and basal membranes ([Figure 1H](#fig1){ref-type="fig"}), revealing that the latter underwent more or less extensive blebbing at the cup-shaped stage ([Figure 1D,I](#fig1){ref-type="fig"}). This blebbing preceded the protrusion of large membrane extensions that were formed hours before the cell exit and were reminiscent of cell shape changes occuring during amoeboid migration ([Figure 1---video 1](#fig1video1){ref-type="video"}). Finally, at the end of the process, Ras-mCherry delineated a transient narrow membrane foot that remained connected to the aorta floor and preceded release in the sub-aortic space ([Figure 1F,G and L](#fig1){ref-type="fig"} and [Figure 1---video 1](#fig1video1){ref-type="video"} and [Figure 1---video 2](#fig1video2){ref-type="video"}).

![Sequential steps and morphological changes during the EHT\
(**A--B**) The EHT is variable in space and time. Schematic representations of (**A**) a zebrafish embryo at 48 hpf; a yellow rectangle shows the region of imaging. (**B**) Left, transversal sections of the dorsal aorta showing the % of cells undergoing emergence (in red) at 0°−20° or 20°--45° angle relative to the dorso-ventral axis (N = 49 cells). The eye looks in the direction of imaging. Right, top view showing variation of the angle of emergence (with the A-P axis as reference). Note that the EHT is also characterized by variability in its time-length, see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and main text. (**C--L**) Live confocal images from 48 hpf *Tg(kdrl:Ras-mCherry; kdrl:eGFP)* embryos. (**C--G**) Images extracted from a 3D-rendering TL sequence (**D--G**) and a Z-stack acquired 120 min before initiation of the time-lapse (**C**), showing the typical changes of cell shape during the EHT (see [Figure 1---video 1](#fig1video1){ref-type="video"}). (**C**) Numbered arrowheads: rim of two cup-shaped EHT undergoing cells. Arrowheads indicate blebs in (**D**) and cellular foots in (**F and G**). isv: intersegmental vessel (see also [Figure 1---video 1](#fig1video1){ref-type="video"}). (**H--L**) Single Z-planes corresponding to cell \#2 extracted from the same TL sequence. Arrowheads: cell borders connecting with adjoining endothelial cells (in yellow), the luminal membrane (in red), the basal membrane (in blue), and blebs (in white), respectively (see [Figure 1---video 2](#fig1video2){ref-type="video"}). Time is indicated in hrs:min. Scale bars, 10 μm.](elife-37355-fig1){#fig1}

We then measured the time-to-exit, starting from the onset of imaging at the cup-shaped stage and found that it varied widely, with an average duration of 5.48 hr (n = 66, see [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, right panel (note that we define the cup-shaped stage as the steps at which the angle between the axis tangential to the inner cell border and the plane of the aortic floor evolves from 150 to 90°, see A: middle top panel)). We also imaged the initial phase of the cell bending, starting from a flat-shaped to the cup-shaped stage in order to determine the time required to reach the latter. We followed a limited amount of cells because, in addition to increasing the risk of phototoxicity owing to long hours of laser exposure, it is currently impossible to determine the precise starting point at which EHT committed cells, engulfed in the hemogenic endothelium, will initiate the emergence (hence hampering the precise determination of EHT initiation and duration). The time intervals between the flat morphology to the cup-shaped stage were also very variable, with an average of 6.5 hr (n = 7, see [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}, left panel and [Figure 1---video 3](#fig1video3){ref-type="video"}).

Finally, to quantify the progression of the process, starting from the cup-shaped stage, we manually measured through time the distance between the anterior and posterior poles of the EHT cell (within the plane of the aortic wall), which we will refer to as the A-P luminal distance ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Firstly, we found little correlation between the A-P luminal distance at the beginning of our imaging and the time of exit of the EHT cell (the longest A-P luminal distances did not imply the longest times-to-exit, see [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Secondly, we noticed that the narrowing down of the A-P luminal distance did not occur at a uniform pace, but with phases of contraction and of relative stabilization of variable durations taking place in the limit of an A-P luminal distance of approximately 2 µm, followed by steep decrease until the release of the cell (this fast drop may represent a collapse following the culmination of mechanical tensions). Hence, the heterogeneous duration of the EHT might be explained by these discontinuities, but the reason for this is unknown.

Intercellular junctions and apical constriction of EHT cells are anisotropic {#s2-2}
----------------------------------------------------------------------------

A specific feature of the EHT is that EHT cells maintain contact with their endothelial neighbors until the very end of the process. This is most probably because of the need to maintain the tightness of the endothelium. In order to visualize the local density and spatial organization of junctional complexes established between EHT cells and contacting endothelial neighbors, we followed ZO1, a protein that interacts preferentially with tetraspan membrane constituents of tight junctions, and also with α-catenin (hence with cadherin complexes, \[[@bib40]\]). We performed live-imaging of hemogenic regions of the aortic floor using *Tg(fli1:Gal4; UAS:RFP; UAS:eGFP-ZO1)* ([@bib20]) embryos (with cytosolic RFP facilitating the localization of cells in the ventral side of the aorta whose increase in thickness indicates hemogenic potential). We observed a heterogeneous density of eGFP-ZO1 at the interfaces between EHT cells and their endothelial neighbors, with an apparent increase at the anterior and posterior poles of the cell that persisted until their convergence to apparent coalescence, shortly before cell exit ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---video 1](#fig2video1){ref-type="video"}).

![Apical constriction undergoes pulsatile activity.\
(**A**) Maximum projection of Z-planes extracted from a spinning-disk confocal TL sequence performed on a 48 hpf *Tg(fli1:Gal4; UAS:RFP; UAS:eGFP-ZO1*) embryo. Yellow arrowheads: regions enriched with eGFP-ZO1, at the two opposite poles of the EHT cell contacting endothelial neighbors and converging until coalescence (see [Figure 2---video 1](#fig2video1){ref-type="video"}). Time is indicated in hr:min. Scale bars, 10 μm. (**B--C**) Spatio-temporal analysis of two cells (see also [Source code 1](#scode1){ref-type="supplementary-material"}). Top panels obtained from the cell visualized in (**A**) and bottom ones from a second cell. (**B**) Tracking of two spots delineating regions of eGFP-ZO1 densification, after maximum projection. Top and bottom panels are showing tracks of antero (black) and posterior (green) eGFP-ZO1 spots for a single cell each. X and Y correspond to the antero-posterior and dorso-ventral axis, respectively. Each point corresponds to the position in X,Y of the spot at a given time point. The lines link two successive time points. Note that when one spot is not detected, the line is interrupted. The anterior track is the longest track in 30% of cases, n = 10 (not shown); The posterior track is the longest track in 60% of cases, n = 10 (bottom panel); note that in 1/10 cells, the displacement of the antero and posterior spots were virtually equal (top panel). (**C**) Evolution as a function of time of distances (green) and closing speeds (red) of the two eGFP-ZO1 spots. Note that breaking of tracks and lines result from sporadic loss of signal. (**D**) Representation of the calculated periods of oscillatory closing speeds (39.7 min ±2.6 min). Error bars represent mean values ± SEM (n = 8 TL sequences).](elife-37355-fig2){#fig2}

We then tracked semi-automatically the displacement of these eGFP-ZO1 enriched regions at the poles and used them as reference to follow the apical constriction as they converge concomitant to the closure of the circumferential junctional belt. This complemented, with a higher spatio-temporal resolution, our results presented in [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} on the variability of the temporal course of the EHT process per se and led to two main conclusions. Firstly, the spots of eGFP-ZO1 high density at the two opposite poles of the EHT cell moved mainly along the A-P axis, often with an imbalance of migration distance ([Figure 2B](#fig2){ref-type="fig"} and legend). Secondly and importantly, the distance between the two eGFP-ZO1 high-density regions decreased non-uniformly ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), with phases of contraction and relative stabilization (already visible in [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and better resolved spatio-temporally here owing to semi-automatic tracking, see Materials and methods). The successive phases of contraction and stabilization are characterized by oscillations of the closing speed of relatively homogenous periodicity ([Figure 2C,D](#fig2){ref-type="fig"}), each oscillation resulting from acceleration and deceleration phases. The oscillations taking place during the contraction phases are the largest in amplitude and are interspersed by short periods of time during which the progression of the A-P distance reaches a minimum (referred to as pseudo-plateaus, see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This oscillatory behavior of the apical constriction is reminiscent of the pulsatile/oscillatory behavior observed in several morphogenetic events during development ([@bib36]), although with significant differences in the biomechanical parameters of these oscillations (see Discussion).

We then thought of investigating more systematically the localization of eGFP-ZO1 in junctional regions across the entire aortic wall, as well as using the delineation of cell contours by this reporter to study in detail the EHT cellular landscape, notably the morphology of EHT cells and adjoining endothelial ones. Precise morphological information on the aortic cellular landscape is difficult to extract from Z projections or 3D views, and projections mask structures in the medial Z planes and distort distances. This prompted us to develop a specialized software tool able to unwrap the signal of the roughly cylindrical cell layer of the aorta onto a plane (2D plane images will be referred to as 2D-maps thereafter). This software allows the treatment of information through time, taking into account heterogeneities and variations in the shape of the aorta along its axis using semi-automatic adjustment of the surface (see [Figure 3A](#fig3){ref-type="fig"} and Materials and methods for details). Using this software, applied mainly to eGFP-ZO1 TL sequences, we obtained a series of significant results.

![The EHT cellular landscape unravelled by 2D-projection.\
Schematic representations of: (**A**) Successive steps leading to the 2D projection (see text, Materials and methods and [Source code 2](#scode2){ref-type="supplementary-material"}), (**B**) The angle at which the Z-projections in the top panels (**C--E**) are visualized (eye) and indicating the back-sided exit of the EHT cell e2. (**C--E**) Top panels are maximum projections of Z-planes extracted from a spinning-disk confocal time-lapse performed on a 48 hpf *Tg(fli1:Gal4; UAS:RFP; UAS:eGFP-ZO1)* embryo. Bottom panels have been obtained after duplication (**x2**) of the corresponding 2D-maps (see Materials and methods and [Figure 3---video 1](#fig3video1){ref-type="video"}). Numbers indicate individual cells. e1, e2: EHT cells (in red, with e1 dividing into e1', e1'' by symmetric division, panel D red arrows) are located on the aorta floor. Cells 6, 9 and 10 are exclusively on the backside. All the others span mainly the front side. Yellow arrowheads: Increased density of eGFP-ZO1 at contacting regions between EHT or endothelial cells that are oriented perpendicular to blood flow (antero-posterior axis). Blue arrow: space between the two daughter cells. Note that in panel (**E**), the daughter cells have emerged (red arrows). Time is indicated in hr:min. Scale bars, 10 μm.](elife-37355-fig3){#fig3}

Firstly, at 48 hpf, as exemplified in [Figure 3C--E](#fig3){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}, the aortic circumference spans over three cells along most of its length.

![Intercellular contacts between hemogenic cells are reinforced.\
(**A**) Top panel: maximum projection of Z-planes extracted from a confocal TL sequence performed on a 48 hpf *Tg(fli1:Gal4; UAS:RFP; UAS:eGFP-ZO1)* embryo. e1; EHT cell, red arrow. Cell three localises on the back-side and partly surrounds the EHT cell (white arrow) (see also the 2D-map, bottom panel). Bottom panel: black arrows point at bicellular interfaces between endothelial cells, enriched with eGFP-ZO1 and perpendicular to the aorta flow. Blue arrows: tricellular junctions between endothelial cells. In the hemogenic region (yellow dotted rectangle), the red arrows point at tricellular junctions between potentially hemogenic cells and the EHT cell (e1, red) that are enriched with eGFP-ZO1 (see [Figure 4---video 1](#fig4video1){ref-type="video"}). Scale bars, 10 μm. (**B**) Schematic representation of the hemogenic region in (**A**) emphasizing on the localization of tricellular junctions mainly between the EHT cell and a neighboring potentially hemogenic cell (e1, 2) and between two potentially hemogenic cells (2, 4). See Materials and methods for the definition of cell categories. (**C**) Number of cells surrounding EHT cells calculated from 2D-maps (see Materials and methods) at an early time point of the process (beginning of the TL sequence; T1, n = 6 maps), and at a late time point contemporary to emergence (T2, n = 2 maps). The green points represent values calculated from the 2 TL sequences for which emergence could be captured. Red bars, median. (**D**) Morphometric analysis of EHT cells at advanced cup-shaped stage, potentially hemogenic and endothelial cells calculated from 2D-maps (see also [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Left: Size. The EHT cells advanced in the process exhibit nearly equal length (15.7 ± 1.6 μm) and width (17.0 ± 0.9 μm), potentially hemogenic cells that are elongated in the antero-posterior axis (length and width of (57.4 ± 5.2 μm) and (23.2 ± 2.5 μm)) and endothelial ones that have a larger width (length and width of (57.7 ± 2.5 μm) and (43.6 ± 2.6 μm)). Right: Area. Error bars represent mean values ± SEM. Unpaired t test (\*\*) p\<0.01; (\*\*\*\*) p\<0.0001 (n = number of maps).\
10.7554/eLife.37355.014Figure 4---source data 1.[Figure 4D](#fig4){ref-type="fig"} Numerical data (width, length and area) and corresponding 2D-Maps with the contours of EHT cells (red), hemogenic cells (blue) and endothelial cells (green).](elife-37355-fig4){#fig4}

Secondly, its cellular landscape is composed of two major populations of cells, displaying similar A-P length but a different aspect ratio; one spanning the aortic floor and distinctly narrower in the medio-lateral axis, and the other one spreading across the entire aortic wall, including occasionally the floor ([Figure 4B,D](#fig4){ref-type="fig"} and legend). In the TL sequence from which images presented in [Figure 3C--D](#fig3){ref-type="fig"} were extracted (see [Figure 3---video 1](#fig3video1){ref-type="video"}), the cells of the former population (cells e1 and e2) underwent shrinkage along the A-P axis, and performed an EHT. These data support the idea that the laterally narrower cells spanning the aortic floor constitute the hemogenic endothelium.

Thirdly, hemogenic cells are capable of performing mitosis contemporarily to their EHT, as exemplified in [Figure 3C,D](#fig3){ref-type="fig"} in which cell e1 divided symmetrically (based on their morphology) along the A-P axis. After mitosis, the daughter cells continued their shrinkage along the A-P axis until their emergence. Mitosis during EHT took place in the aortic plane in 16% of our TL sequences, and in the sub-aortic space in 31% of them.

Fourthly, the junctions between EHT cells and their neighbors are characterized by increased density of eGFP-ZO1, particularly at the level of tricellular junctions and contacting surfaces that are oriented more or less aligned with the medio-lateral axis ([Figure 3C](#fig3){ref-type="fig"} (cells e1 and e2), [Figure 4](#fig4){ref-type="fig"} and [Figure 3---video 1](#fig3video1){ref-type="video"}, [Figure 4---video 1](#fig4video1){ref-type="video"}). During the EHT, these regions of high junctional density flanking the EHT cell converged while the cell apex constricted and merged ([Figure 4A](#fig4){ref-type="fig"} and [Figure 3---video 1](#fig3video1){ref-type="video"}), confirming what we described in [Figure 2A](#fig2){ref-type="fig"}. At the end of the process, the junctional contacts newly established between adjoining endothelial cells merged into a single line of high eGFP-ZO1 density oriented perpendicular to blood flow ([Video 1](#video1){ref-type="video"}, t = 07:00, yellow arrowheads).

###### Dynamic 2D-maping of the apical constriction followed by eGFP-ZO1.

Spinning-disk TL confocal sequence performed on a 48 hpf *Tg(fli1:Gal4; UAS:RFP; UAS:eGFP-ZO1)* embryo, showing a cell undergoing the EHT and processed with the 2D-algorithm. Only the eGFP channel is shown. Note that this is a particular example of an EHT whose axis of emergence diverges by an angle of approximately 45°, from the A-P axis. Yellow arrowheads point at regions of high eGFP-ZO1 density (well visible at t = 03:02). Regions of high eGFP-ZO1 density converge (t = 03:32) to reach coalescence (t = 04:14). At the end of the process, the junctional contacts between adjoining endothelial cells merge into a single eGFP-ZO1-enriched line oriented perpendicular to blood flow. Time is indicated in hr:min. Scale bars, 10 μm.

10.7554/eLife.37355.016

Fifthly, the bijunctional interfaces between endothelial cells that are not in contact with EHT cells and are oriented perpendicular to the A-P axis also often exhibit an apparent increase in eGFP-ZO1 density ([Figure 4A](#fig4){ref-type="fig"}). Hence, we are tempted to deduce that the increase in tight junction components at bi- and tricellular contacts is aimed at reinforcing membrane interfaces that are under high mechanical tension. This would be consistent with the proposed function of tight junctions in the cross-talk with VE-cadherin dependent control of cell-cell tension ([@bib57]).

Finally, the number of EHT surrounding cells does not vary much during the EHT, with an average of five contacting cells at the beginning, getting down to three at the end of the process ([Figure 4C](#fig4){ref-type="fig"}). In the case of EHT cells undergoing mitosis, the daughter cells were spread apart from each other by junctions being established between two adjoining endothelial cells ([Figure 3D](#fig3){ref-type="fig"}, blue arrow).

Circumferential actin is organized anisotropically {#s2-3}
--------------------------------------------------

Most cases of morphogenic movements of tissues during development involve changes in cell geometry that rely on the longitudinal, medial-apical and/or circumferential contraction of actomyosin complexes composed of non-muscular myosin II ([@bib18]; [@bib43]).

In order to investigate actomyosin function in the morphological changes taking place during the EHT, particularly in the contraction of the circumferential junctional belt, we first looked at the localization of filamentous actin (F-actin) in the vascular system, using Lifeact-eGFP as a reporter (Lifeact is a small non interfering peptide of 17 amino acids that allows visualization of actin dynamics and stains filamentous actin). We observed the recruitment of Lifeact-eGFP mainly at the cortico-apical side of the EHT cell, assembled as a belt at the interface with its endothelial neighbors with an apparent enrichment at its A and P poles ([Figure 5A](#fig5){ref-type="fig"}, upper two rows). The 2D-map algorithm revealed F-actin enrichment at contacting surfaces that are more or less perpendicular to the blood flow ([Figure 5A](#fig5){ref-type="fig"}, bottom panels). This localization is very similar to what we observed with eGFP-ZO1, suggesting that F-actin contributes to the organization of sub-junctional regions and perhaps the stabilization of junctional complexes that are, as proposed before, the most exposed to mechanical tension. In addition, the data also support the idea that the apical constriction of EHT cells requires the contractile activity of a circumferential actomyosin belt.

![Actin localization and dynamics.\
(**A--B**) Lifeact-eGFP expressing 48 hpf embryos were imaged by spinning-disk confocal microscopy to obtain maximum projections of Z-planes (A, top and B), single Z planes (A, middle), or 2D-map projections (A, bottom; note that cells \#2 and \#3 are from the same aorta; see also [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Yellow arrowheads: spots enriched with F-actin and aligned with the antero-posterior axis. (**B**) Images extracted from [Figure 5---video 1](#fig5video1){ref-type="video"}. F-actin is enriched at the level of the contracting circumferential belt (top left) that converts into a ring (top right, blue arrowhead), and subsequently in the foot (red arrowhead). Time is indicated in hr:min. Scale bars, 10 μm.\
10.7554/eLife.37355.018Figure 5---source data 1.[Figure 5A](#fig5){ref-type="fig"}: Z-projections (on top) and full 2D-Maps (bottom) from which the images presented in the bottom panels of [Figure 5A](#fig5){ref-type="fig"} were extracted.](elife-37355-fig5){#fig5}

TL sequences performed with embryos expressing Lifeact-eGFP allowed us to follow the dynamics of cortico-apical circumferential actin ([Figure 5---video 1](#fig5video1){ref-type="video"}, with its most informative images composing [Figure 5B](#fig5){ref-type="fig"}). This confirmed and extended our previous results, showing (i) an apical contractile actin belt that ultimately shaped into a contractile ring upon the narrowing down of the A-P luminal distance and (ii) the subsequent formation of an F-actin enriched foot that preceded the full release of the cell. We speculate that this latter pool of F-actin may result from the dissolution of the belt, and might serve as a propeller to trigger mechanical force required to complete the exit and/or the mechanical uncoupling of cell-cell junctions.

Hemodynamic forces control the morphodynamics of the emergence {#s2-4}
--------------------------------------------------------------

The anisotropic organization of F-actin and ZO1 in hemogenic and EHT cells, with their enrichment at the antero-posterior poles more or less aligned with the blood flow axis, suggested that hemodynamic forces may have an influence on the cytoskeleton architecture in these cells as well as on the cytoskeletal/junctional interface. The involvement of blood flow in hematopoiesis was initially shown in seminal work in the zebrafish ([@bib47]) in which the abrogation of heart beating and blood circulation impaired arterial identity and HSC formation (using the silent heart (sih) mutant of cardiac troponin T \[[@bib50]\]). Hence, to question the involvement of hemodynamic forces on the cytoskeleton of hemogenic cells and, more broadly, the dynamics of HSC emergence, we interfered with heart beating using a sih morpholino (injected in *Tg*(*kdrl:Ras-mCherry; kdrl:Lifeact-eGFP)* embryos to visualize F-actin and cellular membranes). We observed, in addition to major alterations in the morphology of the dorsal aorta ([Figure 6A](#fig6){ref-type="fig"}), the recurrent absence of EHT cells with cup-shaped morphology and emerging toward the sub-aortic space (14 embryos injected with the sih morpholino were carefully analysed, all along the dorsal aortic wall). Rather, the aortic floor was decorated with ovoid cells, with their luminal/apical membrane protruding into the lumen of the aorta ([Figure 6B](#fig6){ref-type="fig"}). The lumen also contained cells labelled with Lifeact-eGFP and Ras-mCherry (hence from vascular origin and supposedly having performed their extrusion from the surrounding aortic wall since circulation is abrogated and cells in the aortic lumen do not migrate extensively in comparison to cells in the sub-aortic space, see [Figure 6---video 1](#fig6video1){ref-type="video"} for Z-sectioning of the aorta and visualization of the content of the aortic lumen). TL sequences performed in the trunk region revealed that the ovoid cells in the aortic floor do undergo mitosis and are able to emerge either toward the sub-aortic space or, more unexpectedly, toward the aortic lumen ([Figure 6---video 2](#fig6video2){ref-type="video"}, right), which we never saw in the control condition (this intra-aortic emergence was observed in 3/3 movies obtained from three independent injection experiments). Interestingly, in one of our TL sequences (1/3, the longest TL sequence that lasted 13.30 hr), two of the released cells ended up bursting into pieces (see [Figure 6---video 2](#fig6video2){ref-type="video"}, left), suggesting that cells released in the absence of mechanical constraints exerted by blood flow are prone to cell death. This is consistent with previous studies showing a reduction in the number of hematopoietic stem cells and progenitors upon sih morpholino treatment (in particular in the caudal hematopoietic tissue, see Murayama et al., 2006; [@bib44]; [@bib6]).

![Blood flow influences the morphology as well as the cytoskeletal and junctional organization of hemogenic and emerging cells.\
Lifeact-eGFP (**A,B**) or eGFP-ZO1 (**C**) expressing 48 hpf embryos (**A,B**) were imaged by confocal microscopy after injection of sih or control morpholinos. (**A**) Transversal views of control and sih morphants show the flattening of the aorta and the decrease in perimeter when blood flow is abrogated. Yellow stars indicate the aortic lumen and the red star an EHT cell emerging from the ventral floor. (**B**) Maximum projections of Z-planes (top panels), single Z planes (middle panels and see [Figure 6---video 1](#fig6video1){ref-type="video"}), or 2D-map projections (lower panels). Dashed yellow brackets highlight the thickness of the aorta. Yellow rectangles surround EHT undergoing cells. The same cells visualized after 2D projections are surrounded by red rectangles. Red arrowheads point at actin densification, in EHT cells, aligned with the antero-posterior axis of the dorsal aorta. (**C**) Maximum projections showing eGFP-ZO1 localization in two hemogenic control and sih morphants cells lying on the aortic floor. Note the mosaicism owing to transient expression of the UAS:eGFP-ZO1 transgene (for a 3D-rendering view and visualizing the aortic contours, see [Figure 6---video 3](#fig6video3){ref-type="video"}). Dashed lines indicate the position of the aortic floor. Scale bars, 10 μm.](elife-37355-fig6){#fig6}

Altogether, these results support the idea that hemodynamic mechanical forces contribute to the inward bending of the apical/luminal membrane of EHT cells (the cup-shaped cells) as well as the direction of the emergence (toward the sub-aortic space). They also suggest that the biomechanics of the emergence may impact downstream cellular functions and/or commitments that, if not fulfilled, impede cell survival. Interestingly, when heart beating and blood flow were temporarily arrested using tricaine methanesulfonate (at 1 mg/ml), the inward bending of the apical/luminal membrane was not observed anymore and cells performing the emergence toward the sub-aortic space maintained their path (10 embryos were observed, all along the dorsal aortic wall, between a time window of 35--135 min after interruption of blood flow, data not shown). This result strongly supports the idea that components of hemodynamic forces (among which the mechanical strain, the force perpendicular to the flow axis acting on the vascular wall) are exerting a direct action on the apical/luminal membrane bending.

Finally, we also investigated the effect of obliterating blood flow on F-actin and ZO1 organization. We managed to obtain reasonably good images after 2D-maping with the *Tg*(*kdrl:Ras-mCherry; kdrl:Lifeact-eGFP)* fish line, although with difficulties because of the strong distortion of the aortic shape in the sih embryos. Images clearly revealed a perturbation of F-actin organization in EHT cells, with little reinforcement of that staining at the antero-posterior poles of the cells in comparison to the control ([Figure 6B](#fig6){ref-type="fig"}, bottom panels). Unfortunately, in the case of eGFP-ZO1, fluorescence signals in the sub-cortical regions of hemogenic cells were too low and aorta too distorted to perform 2D-maping. However, 3D-projections and 3D-analysis with the Imaris software also revealed changes in eGFP-ZO1 localization in cells of the hemogenic endothelium, with altered recruitment at the sub-plasmalemmal level and apparent increase of the eGFP-ZO1 cytoplasmic pool ([Figure 6C](#fig6){ref-type="fig"} and see [Figure 6---video 3](#fig6video3){ref-type="video"} for 3D-Imaris rendering). Altogether, these results support the idea that hemodynamic forces exert an action on the cytoskeletal architecture of hemogenic cells and impact on junctional organization.

EHT sequential steps and key features {#s2-5}
-------------------------------------

Time-lapse imaging of Lifeact-eGFP in embryos in which the EHT cells were best aligned with the A-P axis also suggested an active role of the adjoining endothelial cells in the process. The A and P neighbors moved toward each other over the actin-rich poles and appeared to extend actin-rich filopodia to establish contacts. Subsequently, filopodia anastomosis should contribute to the sealing of the aorta floor ([Figure 7---video 1](#fig7video1){ref-type="video"}, with the main sequential steps composing [Figure 7](#fig7){ref-type="fig"}, left panels).

![Modeling of the EHT process.\
Left panels: Lifeact-eGFP expressing 48 hpf embryo imaged by spinning-disk confocal microscopy to obtain single Z planes. Images were extracted from [Figure 7---video 1](#fig7video1){ref-type="video"}. Grey arrows: evidence for the deployment of pushing forces by adjoining endothelial cells. Yellow arrowheads: Lifeact-eGFP densifications. White arrowhead: extension and convergence of filopodia hypothetically emanating from an endothelial cell. Asterisk: intracellular cavity resulting from invagination of the luminal membrane. Middle and right panels (lateral views and 'en face' views (with the eye positioned in the aorta lumen)): schematic drawings representing five sequential steps of the EHT deduced from the localization of eGFP-ZO1 (green lines: junctional interfaces), Ras-mCherry (red and blue: luminal and basal membrane, respectively), Lifeact-eGFP (grey, F-actin circumferential belt. Note that the junctional circumferential belt is not drawn for simplicity). Grey arrows: putative pushing forces deployed by adjoining endothelial cells. Black arrow: hemodynamic force (perpendicular to the aortic plane). Note that in the 'en face' views, the luminal membrane should appear as a red surface (depicted by red lines only), and that the circumferential junctional and F-actin belts are only depicted at their sites of increased density, that is membrane interfaces at the A-P poles of the EHT cell, bound by tricellular junctions oriented perpendicular to blood flow, as revealed by 2D-maps. See the main text for additional comments. C1-C4: adjoining endothelial cells. Time is indicated in hr:min. Scale bar, 10 μm.](elife-37355-fig7){#fig7}

The live-imaging data presented so far led us to define the main, sequential steps of the EHT (see the cartoons illustrating steps 1--5, [Figure 7](#fig7){ref-type="fig"}, middle and right panels, and details in the legend). We propose that the key features of the process are: (i) the initiation of the bending of an hemogenic cell toward the sub-aortic space (with its antero-posterior axis more or less aligned in the direction of blood flow and the inward bending of its luminal/apical membrane depending on hemodynamic forces); (ii) the anisotropic organization of circumferential F-actin and of junctional contacts influenced by the blood flow (with enrichment at trijunctions and membrane interfaces perpendicular to blood flow/aorta A-P axis); (iii) the anisotropic, stepwise and oscillatory constriction of the cell apex, accompanied by concomitant contraction of a circumferential F-actin belt (essential molecular components of this contractile activity are myosin and associated light chains, see below); (iv) the apparent deployment of pushing forces by adjoining endothelial cells possibly contributing to cellular bending and apical constriction; (v) the extension of filopodia by adjoining endothelial cells; (vi) the anastomosis of filopodia to seal the aortic floor; (vii) the release of the EHT cell after remodelling of the luminal membrane (see Discussion) and down-regulation of remaining junctional complexes.

Myosin regulatory light chains 9a and 9b are required for definitive hematopoiesis {#s2-6}
----------------------------------------------------------------------------------

We then addressed the mechanism of contractility of the circumferential actin belt by investigating the role of myosin and, more specifically, the regulation of its activity by myosin regulatory light chains (RLCs). We focused on the regulatory light chain 9 (Myl9) because the *myl9* gene was shown to be a target of Runx1 in a genome-wide analysis of the transcriptional profile and of Runx1 binding in a model of the mouse hemogenic endothelium in cell culture ([@bib37]). Owing to gene duplication in teleosts, the *myl9* gene was duplicated in the zebrafish, leading to the expression of two paralogs bearing more than 93% identity and referred to as Myl9a and Myl9b (for sequence comparison, see [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). By WISH, we confirmed that the *myl9a* mRNA is expressed in the dorsal aorta of 48 hpf embryos ([Figure 8A](#fig8){ref-type="fig"}) and we found that so is the case for *myl9b*. More precisely, we detected the *myl9b* mRNA in the brain, somites, and dorsal aorta (owing to strong signals in the ventral part of the somites, transverse sectioning was necessary to visualize unambiguously the localization of *myl9b* mRNA in aortic cells, [Figure 8A](#fig8){ref-type="fig"}, right panel).

![Myosin regulatory light chains 9a and 9b are required for definitive hematopoiesis.\
(**A**) In situ hybridizations of 48 hpf embryos. Left panels, whole mount; right panel, transversal section. a, aorta; n, notochord; nt, neural tube; s, somites; v, vein; ye, yolk extension; ys, yolk sac. Results were obtained from four independent experiments. Note that for the 25/125 embryos in the top panel, the myl9a signal in the aorta was weaker and masked by the somitic staining. (**B,C**) Maximum projection of Z-planes obtained from 48 hpf *Tg(CD41:eGFP)* embryos, focusing either on the AGM region (**B**), or on the CHT (**C**). Scales bars, 50 μm (**B**); 100 μm (**C**). Only the CD41:eGFP^+^ cells above the yellow dashed line were counted (**C**), as those beneath are not necessarily hematopoietic cells ([@bib30]). (**D,E**) Effect of myl9a and myl9b morpholinos (e2i2 and e3i3, respectively, see Materials and methods for details and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}) based knockdown on the number of CD41:eGFP^+^ cells in the AGM (**D**) and the CHT (**E**). Similar results, in the AGM and in the CHT, were obtained at lower quantities of morpholinos (see [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). n = indicate the numbers of embryos. (**B, E, F**) Error bars represent mean values ± SEM. Unpaired t test (\*\*) p\<0.01; (\*\*\*) p\<0.001.](elife-37355-fig8){#fig8}

We next investigated the incidence of decreasing the expression level of Myl9a or Myl9b on definitive hematopoiesis. We designed two pairs of splice-blocking morpholinos targeting each mRNA (morpholino efficiencies were validated by qPCR, see [Figure 8---figure supplement 1B,C](#fig8s1){ref-type="fig"}), and injected them in *Tg(CD41:eGFP)* embryos. The overall development and blood circulation of injected embryos appeared normal. GFP-positive cells were then scored at 48 hpf, in the sub-aortic space (AGM) (to be most proximal to the site of HSPCs emergence), and in the caudal hematopoietic tissue (CHT), the first niche where aorta-derived HSPCs home. In both knock-downs, we observed a significant decrease in HSPC number in the AGM and the CHT ([Figure 8B--E](#fig8){ref-type="fig"}). This phenotype was phenocopied by two additional morpholinos targeting myl9b and myl9a mRNAs respectively and was rescued for the spe3i3 myl9b morpholino ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). These data support the involvement of both Myl9a and Myl9b in definitive hematopoiesis, and possibly in the EHT process.

Finally, in order to address the intracellular localization and dynamics of the two Myl9 isoforms during the EHT, we generated *Tg*(*kdrl*:Myl9a-eGFP) and *Tg*(*kdrl:Myl9b-eGFP)* fish lines. Since the fluorescence intensities of Myl9a and Myl9b fused to eGFP were much lower than in the case of Lifeact-eGFP, we were unable to treat our movies with the 2D algorithm. However, as seen in [Video 2](#video2){ref-type="video"}, regular TL sequences show convincingly that Myl9a-eGFP and Myl9b-eGFP assemble as cortico-apical belts with enrichment at spots between EHT cells and neighbors that move, upon apical constriction, along the A-P axis, and coalesce. This is reminiscent of what we observed with Lifeact-eGFP and eGFP-ZO1 (see [Video 3](#video3){ref-type="video"} for a comparative 'en face' visualization of the dynamics of actin and myosin belts/rings). We also noticed that Myl9a and b were recruited at the contracting cytokinesis ring in EHT cells that underwent mitosis (see [Video 2](#video2){ref-type="video"} and its legend).

###### Dynamics of Myl9a and Myl9b during the EHT.

Top panels: Maximum projection of Z-planes of a laser scanning confocal TL sequence performed on a 48 hpf *Tg(kdrl:Ras-mCherry; kdrl:Myl9a-eGFP)* embryo focusing on the localization of Myl9a-eGFP at the circumferential belt and its accumulation at the two opposite poles aligned with the A-P axis (t = 01:25). Note the progression of belt closure (t = 01:50) and the coalescence of the two points at the end of the EHT (t = 02:30). Note the independent migrating cell coming into contact with the EHT cell (t = 01:40). Note also that the cell divides after the release and that Myl9a-eGFP is recruited to the cytokinesis ring (white arrow, t = 02:55). Time is indicated in hr:min. Scale bars, 10 μm. Bottom panels: Maximum projection of Z-planes of a spinning-disk confocal TL sequence performed on a 48 hpf *Tg(kdrl:Gal4; UAS:RFP; kdrl:Myl9b-eGFP)* embryo focusing on accumulation of Myl9b-eGFP at the cell borders connecting with neighboring cells (t = 00:12) and at a luminal circumferential belt that coalesces at the end of the EHT (t = 00:36 and 03:06 respectively, yellow arrowheads). Note that the cell divides after the release and that Myl9b-eGFP is recruited to the cytokinesis ring (white arrow at t = 08:56). Time is indicated in hr:min. Scale bars, 10 μm.

10.7554/eLife.37355.029

###### Dynamics of the contractile and anisotropic actin and myosin rings.

Spinning-disk confocal TL sequence showing 3D rendering 'en face' views of EHT cells from 48 hpf *Tg(fli1:Lifeact-eGFP)* (top panel), *Tg(kdrl:Myl9a-eGFP)* (middle panel) and *Tg(kdrl:Myl9b-eGFP)* (bottom panel) embryos. White arrows point at Lifeact-eGFP (t = 01:46), Myl9a-eGFP (t = 01:30) and Myl9b-eGFP (t = 02:22) accumulations at the two opposite poles of the EHT cells that are more or less perpendicular to blood flow and aligned with the A-P axis (white arrowheads are positioned parallel to that axis). Note the conserved anisotropy of the belt through time and the dynamics of its closure. Time is indicated in hr:min. Scale bars, 5 μm (top and bottom panels) and 10 μm (middle panel).

10.7554/eLife.37355.030

The amino-terminal phosphorylation site on Myl9b is essential for definitive hematopoiesis {#s2-7}
------------------------------------------------------------------------------------------

Myl9b and Myl9a are very similar (93% identity calculated by ClustalO), and the most significant difference resides in their amino-terminus, where the two serines following the starting methionine (which are strictly conserved in mammals and in most zebrafish RLCs, see [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}) are present in Myl9b, but not in Myl9a. These two residues are the substrates of protein kinase C (PKC) activity ([@bib21]). It was shown that their phosphorylation impairs the phosphorylation of the downstream Rho-kinase/MLCK/Citron-kinase target site ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}) that is essential for the stimulatory activity of RLCs on the ATPase activity of the myosin heavy chain ([@bib58]). Hence, phosphorylation of this amino-terminal site inhibits myosin activity and actomyosin contraction.

We mutagenized the Myl9b cDNA to substitute the two amino-terminal serine residues by alanines, and expressed the wt or mutant form (Myl9bA2A3) fused to eGFP in zebrafish embryos by transient transgenesis. Expression of the mutant form using the kdrl promoter caused mild morphological alterations of the dorsal vascular system (with maintenance of blood flow, no obvious change in the shape of the dorsal aorta and a few distortions at the base of intersegmental vessels, data not shown). To restrict the expression of Myl9bA2A3 or the wt form to aorta-derived HSPCs, we used the Runx'1 + 23' enhancer ([@bib54]), which we confirmed to drive transient expression specifically in these cells ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Using this promoter, we transiently expressed Myl9b-eGFP and Myl9bA2A3-eGFP in *Tg*(*Kdrl:Ras-mCherry)* embryos to visualize Myl9b-expressing HSPCs together with the vascular system ([Figure 9](#fig9){ref-type="fig"}). At 40 and 50 hpf, and in comparison with the wt form, we found a much lower number of HSPCs expressing the mutant form, both in the sub-aortic space and in the CHT ([Figure 9A,B](#fig9){ref-type="fig"}). These results suggest that preventing N-terminal phosphorylation impairs definitive hematopoiesis and may interfere with the emergence from the aortic floor. Finally, we performed live imaging in this context, and made a series of observations. Firstly, while we occasionally found hemogenic cells in the aortic floor that expressed the wt Myl9b-eGFP and underwent EHT, we were unable to find such cells upon expressing Myl9bA2A3-eGFP, suggesting that the latter cells emerged at a significantly lesser frequency. Secondly, cellular fragments were often seen in the sub-aortic area, usually indicative of cell bursting. This cell fragmentation may have occurred during the EHT as described upon *runx1* knock-down ([@bib29]), or in EHT-derived HSPCs as upon scl-α knock-down ([@bib61]). An example of cell fragmentation probably taking place short after the emergence is shown in [Figure 9C](#fig9){ref-type="fig"} and [Figure 9---video 2](#fig9video2){ref-type="video"}. Thirdly, EHT-derived HSPCs expressing Myl9bA2A3-eGFP exhibited abnormal shapes and migration, characterized by anarchic membrane extensions in many directions at once ([Figure 9D](#fig9){ref-type="fig"} and [Figure 9---video 1](#fig9video1){ref-type="video"}). Interestingly, they were still able to undergo mitosis, with Myl9bA2A3 relocating to the cytokinesis ring as wt Myl9b would do (data not shown).

![The amino-terminal phosphorylation site on Myl9b is essential for definitive hematopoiesis.\
(**A**) Maximum projection of Z-planes obtained from 40 hpf and 50 hpf embryos expressing either Myl9b-eGFP or Myl9bA2A3-eGFP under the control of the runx'1 + 23' enhancer that allows expression in hematopoietic stem cells (see also [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). White dotted lines delineate the embryo. Scale bars, 100 μm. (**B**) Quantification of the number of Myl9b-eGFP or Myl9bA2A3-eGFP positive cells in the AGM and CHT at 40 hpf or 50 hpf. Error bars represent mean values ± SEM. Unpaired t test (\*\*\*) p\<0.001; (\*\*\*\*) p\<0.0001 (n = 11 and n = 12 embryos; the data are representative of two independent experiments, both performed at 40 hpf and 50 hpf). (**C--D**) Maximum projection of Z-planes extracted from spinning-disk confocal TL sequences performed on 40 hpf *Tg(kdrl:Ras-mCherry)* embryos expressing the indicated forms of Myl9b-eGFP. Scale bars, 10 μm. Time is indicated in hr:min. (**C**) White arrowheads, cell debris resulting from bursting (see [Figure 9---video 2](#fig9video2){ref-type="video"}). Similar phenotype was observed in three independent experiments. (**D**) White arrowheads, Myl9b-eGFP accumulation at the rear of a migrating cell (top panel) or at multiple cell extensions lacking Myl9bA2A3-eGFP accumulation (bottom panel). Similar phenotype was observed in four independent experiments. Yellow arrowhead, another migrating cell within the imaging field (see [Figure 9---video 1](#fig9video1){ref-type="video"}).](elife-37355-fig9){#fig9}

Discussion {#s3}
==========

This study led us to envision the adaptation of the EHT to constraints imposed by the aortic environment, in particular the mechanical forces exerted by the blood flow. It strengthens the idea that the process is indeed very unique when compared to other single cell extrusion or delamination processes described so far. The high spatio-temporal resolution of our TL sequences and their qualitative and quantitative analysis, in particular using an appropriate 2D-algorithm, highlight the specific features of the EHT, schematized in [Figure 7](#fig7){ref-type="fig"}. Here, in addition to underlining the peculiarities of the EHT, we propose to discuss the results that are most relevant to a comparative analysis of the process with other cellular extrusion mechanisms.

The bending of the apical/luminal membrane and the orientation of the emergence {#s3-1}
-------------------------------------------------------------------------------

The inward bending of the luminal membrane of EHT cells is one of the hallmarks of the EHT that, to our knowledge, has never been described so far for any other type of cell extrusion. In the context of the EHT, the direction of extrusion is opposite depending on the species, i.e towards the sub-aortic space in the zebrafish and the aortic lumen in the mouse ([@bib31]). Although the two emergences proceed in opposite directions, it appears that the EHT, in these two species, may have something in common. Indeed, electron microscopic images of cells of the embryonic mouse aorta floor showed the presence of large intracellular vacuole-like structures ([@bib41]) reminiscent of what is observed in the zebrafish embryo, raising the idea that the inward bending of the apical/luminal membrane may be followed by its intracellular release after the emergence.

If the reason for the discrepancy regarding the direction of the emergence between the mouse and the zebrafish is currently unknown, this study contributes shedding light on this issue. When abrogating the blood flow by obliterating heart beating from the very beginning, we show that cells from the aortic floor can emerge in the aortic lumen (presumably hemogenic cells endowed with the potential to become hematopoietic). Unless, in the zebrafish, hemogenic cells that have never been exposed to hemodynamic forces do not express the relevant cytosolic machineries essential for performing a sub-aortic emergence, this raises the possibility that the variation between the two species is a direct consequence of differences in the strength of components of hemodynamic forces, such as, for example, the mechanical strain (the force perpendicular to the direction of the flow and that relates to the rhythm of heart beating, [@bib16]). However, the differences in heart beating frequencies between the two species are not so far from each other at that developmental stage (approximately 2--3 beats/s, \[[@bib59]; [@bib17]\]). Hence, it is not so clear if the sub-aortic orientation of the emergence of HSCs in the zebrafish may be a direct consequence of the mechanical strain; what might count as well regarding the difference between the two species are the physical properties of the respective aortic walls that should impact the way they respond to the force because of their diameters, much wider in the mouse than in the zebrafish (approximately 300 μm in the mouse and 25 μm in the zebrafish embryos at the time window of the EHT).

Mechanical forces exerted by blood flow control the EHT biomechanics {#s3-2}
--------------------------------------------------------------------

The period of the aortic development during which the EHT takes place is the one at which aortic cells are highly exposed to mechanical tensions. Indeed, it has been shown by using a VE-cadherin mechanical sensor, that young aortic cells (at 48 hpf), are more exposed to tension than 2 days later, when the aorta has matured and the aortic cells align with the direction of the flow ([@bib34]). Hence, elongated hemogenic and EHT cells, on the aortic floor, may also orientate and contract along that same axis (as we show in our work with the 2D-maping results), to minimize environmental constraints and membrane tension. In this context, the membrane interfaces that remain the most exposed to mechanical tensions are most probably the ones that are enriched in ZO1 and actin and are oriented perpendicular to blood flow (consistently with ZO1 enrichment at the interface between endothelial cells that spread over a large surface of the aorta and whose orientation is also perpendicular to blood flow). According to our results obtained upon abrogation of heart beating and showing alteration of actin anisotropy (i.e the reduction in the recruitment of sub-cortical actin at the two poles of the cells more or less aligned with the blood flow axis), tensions exerted by the hemodynamics control sub-plasmalemmal cytoskeletal architecture in EHT cells and, consequently, the actin/junctional interface (as suggested by the delocalization of ZO1 that we observe in these conditions). Altogether, these results support the conclusion that the EHT biomechanics are specifically adapted to - and influenced by - the mechanical tensions exerted by blood flow. It should be noted that this control by the flow might be direct (ex: via cell surface mechanosensors), and/or indirect (ex: via the induction of Runx1, the transcription factor essential for hematopoiesis \[[@bib1]\]). Indeed, hemodynamics and in particular shear stress was shown to control endothelial cell morphology and influence the expression of many transcription factors (for example, for a link between flow, mechanotransduction, actin, transcription see [@bib45]).

Biomechanics of the apical constriction compared to other morphogenetic processes {#s3-3}
---------------------------------------------------------------------------------

The constriction of the apical/luminal side of EHT cells, like many apical cell constriction events described so far, should depend on the activity of actomyosin recruited at the junctional circumferential belt. The membrane interfaces that are the less enriched in actomyosin (oriented along the antero-posterior axis), are the ones that shrink the most, supporting the idea that the constriction is also coupled with their consumption, possibly by endocytosis.

EHT cell apical constriction exhibits peculiar biomechanical characteristics in comparison to other apical constriction mechanisms described so far. It is pulsatile, with successive phases of contraction and of stabilization, each one with a time-length varying stochastically (see [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The pulsatility relies on variations of the apical closing speed that oscillates (owing to acceleration and deceleration cycles), with more or less large amplitudes (with larger amplitudes during the constriction than the stabilization phase) and with periods of approximately 40 min on average. This average period value is longer than in the most extensively studied and quantified processes taking place during development, such as, for example, the apical-medial contraction of cells during ventral mesoderm invagination in *Drosophila melanogaster* embryos (see the seminal article \[[@bib42]\]), or the apical-medial and apical-junctional mediated contractions during neuroblasts ingression (see \[[@bib3]; [@bib51]\]); the latter being more comparable to the EHT process since a single cell extrudes from an epithelium, the ectoderm. In these two processes, for which the duration of the apical constriction takes approximatey 6 min and 30 min, respectively, the period of each pulsatile cycle is in the minute range (with, for example, an average of 3.2 constriction pulses over 6 min for ventral cells (interspersed with inter-periodic intervals of similar values) and of 28.8 constriction pulses over 30 min for neuroblasts (value extrapolated from [@bib51])). Finally, for the EHT, the inter-periodic intervals of the contraction phase take approximately 21 min on average (which we referred to as pseudo-plateaus, see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Currently, the reason for such a discrepancy in the periods of pulsatile cycles of the apical constriction is not known. However, in comparison to the time scale of apical contraction in the neuroblast ingression process that also leads to cell extrusion (lasting for approximately 30 min, as mentioned already), the timescale of the EHT process per se is relatively long (average duration of approximately 10 hr). This suggests that the specific parameters of the oscillations of the apical closing speed for EHT cells that impact on contraction efficiencies (in particular for periods and amplitudes) correlate with the time scale of the whole process, suggesting that they may be controlled at the mesoscopic level, perhaps involving gene regulatory networks controlling cyclic expression of genes (such as in the case of ultradian oscillations that have periods in the time-range of the hour, see [@bib23]). Indeed, EHT cells are integrated into a developing lumenized tissue that is submitted to a series of mechanical tensions owing to aortic morphological maturation including (i) the adaptation of the endothelial wall to EHT cell emergence and the significant reduction of the aortic diameter with time ([@bib22]; [@bib29]; [@bib52]), (ii) the extensive modification of the structure of the sub-aortic space (with the modification of the basal lamina contacting EHT cells and transducing forces via integrins; see the incidence of basal lamina on periods of oscillations \[[@bib15]; [@bib32]\]) and, last but not least, (iii) complex hemodynamic forces. In such environment, the high mechanical tensions might tune the downstream molecular events controlling actin-driven directional forces and actomyosin recruitment and contractility (for the relevance of high-order information, at the tissue level, on the biomechanics and role of contractile pulses and the theoretical description of pulsatile/oscillatory behaviour, see \[[@bib36]\]).

The regulation of actomyosin contraction {#s3-4}
----------------------------------------

In this study, we do show that the contraction of circumferential actomyosin accompanies the constriction of EHT cells; however, we do not show a correlation between apical pulses and oscillatory recruitment of actomyosin components in that specific region as performed in other studies, essentially for technical reasons (the weakness of signals of myosin RLCs fused to fluorescent reporters in all the transgenic lines established is too close to background to allow extraction of oscillatory signals from fluctuating noise). Hence, we can only speculate that the peculiarities of the biomechanical characteristics of apical constriction discussed above rely on the regulation of actomyosin recruitment and contraction. However, interfering with *Myl9b* function by mutagenesis of its PKC phosphorylation site impairs hematopoiesis, which is consistent with the requirement for actomyosin activity during the EHT and points to the importance of a particular regulatory pathway. Indeed, the N-terminal phosphorylation site in *Myl9b*, shared with most other myosin RLCs, was shown to be the substrate of PKC ([@bib21]) and, upon phosphorylation, to prevent the activating phosphorylation of a downstream site (the MLCK site, the most characterized phosphorylation site of RLCs, see \[[@bib58]\]). Hence, this reinforces the possibility that a major regulatory axis of the EHT process relies on controlling actomyosin activity, by regulating a complex interplay between activating and inhibitory kinases. In this scenario, there exists the possibility that *Myl9b*, via the phosphorylation of its N-terminus, contributes to the tuning of the mechanical parameters of the contraction. Finally, there may be additional complexity to the system, for another RLC, *Myl9a*, is expressed in the aorta and may be co-expressed with *Myl9b* in EHT cells. *Myl9a* is a paralog that appears to be more restricted to the zebrafish and lacks the N-terminal, PKC phosphorylation site. Since the knock-down of *myl9a*, as is the case for *myl9b*, impairs definitive hematopoiesis, both isoforms may be involved in the EHT, with a fine tuning of their molecular ratio.

In conclusion, our study reveals key biochemical and biomechanical features of hematopoietic stem cell emergence in the zebrafish embryo and strengthens the significance of the mechanical constraints imposed by the environment and more specifically the blood flow. This work paves the way for future studies on this very unique process, including studying the contribution of forces exerted by the adjoining endothelial cells. Overall, it invites to biophysical modelling to point to the most relevant biomechanical features of the process.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\     Designation                        Source or reference            Identifiers                                                   Additional information
  (species) or\                                                                                                                                     
  resource                                                                                                                                          
  ----------------- ---------------------------------- ------------------------------ ------------------------------------------------------------- -------------------------------------
  Strain, strain\   Zebrafish: AB                      Zebrafish International\       ZFIN:\                                                        
  background\                                          Resource Center (ZIRC)         ZDB-GENO-960809--7                                            
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish Tg(kdrl:HsHRAS\          [@bib8]                        ZFIN ID:\                                                     referred to as Tg(kdrl:Ras-mCherry)
  background\       -mCherry): s916Tg                                                 ZDB-ALT-090506--2                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish:\                        [@bib48]                       ZFIN ID:\                                                     
  background\       Tg(fli1a:LIFEACT-eGFP): zf495Tg                                   ZDB-ALT-140610--8                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish:\                        [@bib4]                        ZFIN ID:\                                                     
  background\       Tg(5xUAS:RFP): nkuasrfp1aTg                                       ZDB-ALT-080528--2                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish:\                        [@bib62]                       ZFIN ID:\                                                     
  background\       Tg(fli1ep:Gal4ff): ubs3Tg                                         ZDB-ALT-120113--6                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish:\                        [@bib20]                       ZFIN ID:\                                                     
  background\       Tg(UAS:EGFP-ZO1): ubs5Tg                                          ZDB-ALT-120113--7                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish:\                        [@bib26]                       ZFIN ID:\                                                     
  background\       Tg(kdrl:EGFP): s843Tg                                             ZDB-ALT-050916--14                                            
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish: Tg(kdrl:gal4;UAS:RFP)   NA                             NA                                                            
  background\                                                                                                                                       
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish Tg(−6.0itga2b:EGFP):\    [@bib38]\                      ZFIN ID:\                                                     referred to as Tg(CD41:eGFP)
  background\       la2Tg                              Traver                         ZDB-ALT-051223--4                                             
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish\                         This Paper                     N/A                                                           
  background\       Tg(kdrl:myl9a-eGFP): ip5Tg                                                                                                      
  (Zebrafish)                                                                                                                                       

  Strain, strain\   Zebrafish\                         This paper                     N/A                                                           
  background\       Tg(kdrl:myl9b-eGFP): ip6Tg                                                                                                      
  (Zebrafish)                                                                                                                                       

  Antibody          Sheep Anti-Digoxigenin\            Roche                          Cat\# 11207733910;\                                           1:5000
                    Fab fragments,\                                                   RRID: [AB_514500](https://scicrunch.org/resolver/AB_514500)   
                    POD Conjugated                                                                                                                  

  Recombinant\      Transposase pCS-zT2TP              [@bib53]                       N/A                                                           
  DNA reagent                                                                                                                                       

  Recombinant\      pUAS:eGFP-hs-ZO1                   [@bib20]                       N/A                                                           
  DNA reagent                                                                                                                                       

  Recombinant\      pEGFP-C1                           Clontech                       N/A                                                           
  DNA reagent                                                                                                                                       

  Recombinant\      pmKate2-f-mem                      Evrogen                        Cat\#: FP186                                                  
  DNA reagent                                                                                                                                       

  Recombinant\      pG1-flk1-MCS-tol2                  [@bib26]                       Addgene\                                                      
  DNA reagent                                                                         plasmid \# 26436                                              

  Recombinant\      PG1-flk-MCS-tol2-kdrl-\            This paper                     N/A                                                           
  DNA reagent       myl9a-eGFP                                                                                                                      

  Recombinant\      PG1-flk-MCS-tol2-kdrl-\            This paper                     N/A                                                           
  DNA reagent       myl9b-eGFP                                                                                                                      

  Recombinant\      p5E-Runx1 + 23-betaglobin          [@bib54]                       Addgene\                                                      
  DNA reagent                                                                         plasmid \# 69602                                              

  Recombinant\      pTol2-Runx1 + 23×1-\               This paper                     N/A                                                           
  DNA reagent       betaglobin:eGFP                                                                                                                 

  Recombinant\      pTol2-Runx1 + 23×1-betaglobin\     This paper                     N/A                                                           
  DNA reagent       -myl9b-eGFP                                                                                                                     

  Recombinant\      pTol2-Runx1 + 23×1-betaglobin\     This paper                     N/A                                                           
  DNA reagent       -myl9bA2A3-eGFP                                                                                                                 

  Recombinant\      pTol2-Runx1 + 23×1-betaglobin\     This paper                     N/A                                                           
  DNA reagent       -myl9a-mKate2                                                                                                                   

  Chemical\         Tricaine                           Sigma Aldrich                  Cat\#: A5040                                                  
  compound, drug                                                                                                                                    

  Chemical\         Methylen Blue                      Sigma Aldrich                  Cat\#: M4159                                                  
  compound, drug                                                                                                                                    

  Chemical\         N-Phenylthiourea (PTU)             Sigma Aldrich                  Cat\#: P7629                                                  
  compound, drug                                                                                                                                    

  Chemical\         Low Melting Point,\                Promega                        Cat\#: V2111                                                  
  compound, drug    Analytical Grade                                                                                                                

  Chemical\         Formaldehyde (FA)                  Polysciences                   Cat\#:04018--1                                                
  compound, drug                                                                                                                                    

  Chemical\         Proteinase K                       Ambion                         Cat\#: AM2546                                                 
  compound, drug                                                                                                                                    

  Chemical\         Digoxigenin labeled\               Jena Bioscence                 Cat\#: NU-803-DIGX                                            
  compound, drug    nucleotides                                                                                                                     

  Chemical\         Wester Blotting\                   Roche                          Cat\#: 11921673001                                            
  compound, drug    Reagent (WBR)                                                                                                                   

  Chemical\         NBT                                Sigma Aldrich                  Cat\#: N6639                                                  
  compound, drug                                                                                                                                    

  Chemical\         BCIP                               Sigma Aldrich                  Cat\#: B-8503                                                 
  compound, drug                                                                                                                                    

  Chemical\         Tissue Freezing\                   Electron Microscopy Sciences   Cat\#: 72592-B                                                
  compound, drug    Medium, Blue                                                                                                                    

  Chemical\         Aqua-Poly/Mount                    Biovalley                      Cat\#: 18606--5                                               
  compound, drug                                                                                                                                    

  Chemical\         Immersol W 2010, oil               Zeiss                          Cat\#:\                                                       
  compound, drug                                                                      444969-0000-000                                               

  Chemical\         AquaSound Clear\                   Free-Med                       Cat\#: FU00071                                                
  compound, drug    ultrasound gel                                                                                                                  

  Commercial\       Cloning Gibson Assembly            NEB                            Cat\#: E2611S                                                 
  assay or kit                                                                                                                                      

  Commercial\       cDNA synthesis for\                Thermo Fisher                  Cat\#: 8080093                                                
  assay or kit      cloning Super Script III                                                                                                        

  Commercial\       Expand High\                       Sigma Aldrich                  Cat\#:11732641001                                             
  assay or kit      Fidelity polymerase                                                                                                             

  Commercial\       RNA synthesis mMESSAGE\            Ambion                         Cat\#: AM1340                                                 
  assay or kit      mMACHINE SP6\                                                                                                                   
                    Transcription                                                                                                                   

  Commercial\       Poly(A) Tailing Kit                Ambion                         Cat\#: AM1350                                                 
  assay or kit                                                                                                                                      

  Commercial\       DNA purification for\              Macherey Nagel                 Cat\#: 740420.10                                              
  assay or kit      injection NucleoBond\                                                                                                           
                    Xtra Midi EF                                                                                                                    

  Commercial\       T7 RNA polymerase                  Promega                        Cat\#: P2075                                                  
  assay or kit                                                                                                                                      

  Commercial\       RNA extraction RNeasy\             QIagen                         Cat\#: 74134                                                  
  assay or kit      Plus Mini Kit                                                                                                                   

  Commercial\       cDNA synthesis for qPCR\           Invitrogen                     Cat\#: 28025013                                               
  assay or kit      M-MLV Reverse Transcriptase                                                                                                     

  Commercial\       RNAse Out                          Invitrogen                     Cat\#: 10777019                                               
  assay or kit                                                                                                                                      

  Commercial\       qPCR Takyon Rox SYBR\              Eurogenetec                    Cat\#: UF-RSMT-B0701                                          
  assay or kit      Master mix blue dTTP                                                                                                            

  Commercial\       NucAwayTM d'AmbionTM               Invitrogen                     Cat\#: AM10070                                                
  assay or kit                                                                                                                                      

  Software,\        Acquisition-Imaging\               Leica                          <http://www.Leica-microsystems.com>                           
  algorithm         analysis-LAS X                                                                                                                  

  Software,\        Acquisition-Volocity               Perkin Elmer                   <http://www.perkinelmer.com/>                                 
  algorithm                                                                                                                                         

  Software,\        Imaging analysis-Imaris\           Bitplane                       <http://www.bitplane.com/>                                    
  algorithm         8.4.1                                                                                                                           

  Software,\        Imaging\                           MathWorks                      <https://fr.mathworks.com>                                    
  algorithm         analysis-Matlab R2017a/R2017b                                                                                                   

  Software,\        Image Analysis-Prism 6             Graph Pad                      <https://www.graphpad.com/>                                   
  algorithm                                                                                                                                         

  Software,\        Image Analysis-Fiji                NIH                            <https://imagej.net/Fiji>                                     
  algorithm                                                                                                                                         

  Software,\        Image Analysis\                    [@bib56]                       <https://imagej.net/TrackMate>                                
  algorithm         TrackMate plugin for Fiji                                                                                                       

  Software,\        Image Analysis Icy                 [@bib11]                       <http://icy.bioimageanalysis.org/>                            
  algorithm                                                                                                                                         

  Software,\        Image Analysis\                    This paper                     This Paper                                                    
  algorithm         TubeSkinner plugin\                                                                                                             
                    for Icy                                                                                                                         

  Software,\        Figures-Photoshop\                 Adobe                          <http://www.adobe.com/cn/>                                    
  algorithm         CC 2017.1.1                                                                                                                     

  Software,\        Figures-Illustrator\               Adobe                          <http://www.adobe.com/cn/>                                    
  algorithm         CC 2017.1.1                                                                                                                     

  Recombinant\      Morpholino\                        Gene Tools                     N/A                                                           CCTCTTACCTCAGTTACAATTTATA
  DNA reagent       Standard Control                                                                                                                

  Recombinant\      Morpholino sih                     [@bib50]                       ZDB-MRPHLNO\                                                  CATGTTTGCTCTGATCTGACACGCA
  DNA reagent                                                                         -060317--4                                                    

  Recombinant\      Morpholino\                        Gene Tools; This paper         N/A                                                           ATTCAGCTTGTATATCTCTCACCCA
  DNA reagent       Myl9aspe2i2                                                                                                                     

  Recombinant\      Morpholino\                        Gene Tools; This paper         N/A                                                           CCCTGGTACAAACACACCGCAGATT
  DNA reagent       Myl9aspi3e4                                                                                                                     

  Recombinant\      Morpholino\                        Gene Tools; This paper         N/A                                                           CTATTATTTCACCCAGACTCACCCA
  DNA reagent       Myl9bspe2i2                                                                                                                     

  Recombinant\      Morpholino\                        Gene Tools; This paper         N/A                                                           TTGTTGTTGTTTTTACCAGATCCCT
  DNA reagent       Myl9bspe3i3                                                                                                                     

  Recombinant\      Oligo:\                            This paper                     N/A                                                           atttaggtgacactatagaagngATGT\
  DNA reagent       Rescue-SP6-myl9b\                                                                                                               CCAGCAAAAGAGCAAAGGGG
                    forward                                                                                                                         

  Recombinant\      Oligo: Rescue-myl9b\               This paper                     N/A                                                           CTACATGTCGTCTTTGTCTTT\
  DNA reagent       reverse                                                                                                                         GGCTCCG

  Recombinant\      Oligo: qPCR myl9a\                 This paper                     N/A                                                           CACCTGCTTCGATGAGGACGCCA
  DNA reagent       forward                                                                                                                         

  Recombinant\      Oligo: qPCR myl9a\                 This paper                     N/A                                                           CCGAGATCTGCTGACCACTATGG\
  DNA reagent       reverse                                                                                                                         GCGATC

  Recombinant\      Oligo: qPCR myl9b\                 This paper                     N/A                                                           GCCTGCTTCGATGAGGAGGGATC
  DNA reagent       forward                                                                                                                         

  Recombinant\      Oligo: qPCR myl9b\                 This Paper                     N/A                                                           CTGACCACCATGGGAGACC
  DNA reagent       reverse                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           CACGTCCAATGTCTTCGCCA
  DNA reagent       splicemyl9asp22\                                                                                                                
                    forward                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           TGGGTTCTTCCCCAGAGAGG
  DNA reagent       splicemyl9asp22\                                                                                                                
                    reverse                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This Paper                     N/A                                                           GGACGCCACTGGGTTCATCC
  DNA reagent       splicemyl9asp34\                                                                                                                
                    forward                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           GTTTCCTTTCTTGTCGATGGGCGC
  DNA reagent       splicemyl9asp34\                                                                                                                
                    reverse                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           GCATCTTTGGGTAAGAACCCGTCTG
  DNA reagent       splicemyl9bsp22\                                                                                                                
                    forward                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           TCAGCCGCTCTCCAAACATG
  DNA reagent       splicemyl9bsp22\                                                                                                                
                    reverse                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           GAGGAGGGATCTGGTTTCATCC
  DNA reagent       splicemyl9bsp33\                                                                                                                
                    forward                                                                                                                         

  Recombinant\      Oligo: qPCR\                       This paper                     N/A                                                           CCCTTCTTGTCAATGGGAGCC
  DNA reagent       splicemyl9bsp33\                                                                                                                
                    reverse                                                                                                                         

  Recombinant\      Oligo: Probe\                      This paper                     N/A                                                           GATAAGGAGGATCTGCATGA\
  DNA reagent       myl9a forward                                                                                                                   CATGCTCG

  Recombinant\      Oligo: Probe T7\                   This paper                     N/A                                                           gaaattaatacgactcactatagg\
  DNA reagent       myl9a reverse                                                                                                                   GTGAAGCGATCGCCCATAGTGG

  Recombinant\      Oligo: Probe\                      This paper                     N/A                                                           GCACGATATGCTAGCATCTTTGGG
  DNA reagent       myl9b forward                                                                                                                   

  Recombinant\      Oligo: Probe\                      This paper                     N/A                                                           gaaattaatacgactcactataggg\
  DNA reagent       T7-myl9b reverse                                                                                                                CATGGTGGTCAGCAGCTCCC

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           TATTTTAACAGACAAGGGCGATGT\
  DNA reagent       PG1-flk-MCS-tol2-myl9a-\                                                                                                        CTGCAGCCAAACGCGCCAAAGGAAAG
                    eGFP-myl9a-for                                                                                                                  

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CCTTGCTCACCATGTCGTCCTTG\
  DNA reagent       PG1-flk-MCS-tol2-myl9a-\                                                                                                        TCTTTGGCTCCGTGCTTTAG
                    eGFP-myl9a-rev                                                                                                                  

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GGACGACATGGTGAGCAAGGGCG\
  DNA reagent       PG1-flk-MCS-tol2-myl9a-\                                                                                                        AGGAGCTGTTCACCGGG
                    eGFP-eGFP-for                                                                                                                   

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CGATATCCTCGAGGGTACCGTTATCTA\
  DNA reagent       PG1-flk-MCS-tol2-myl9a-\                                                                                                        GATCCGGTGGATCCCGGGCCCGC
                    eGFP-eGFP-rev                                                                                                                   

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GACGTTATTTTAACAGACAAGGGCG\
  DNA reagent       PG1-flk-MCS-tol2-myl9b-\                                                                                                        ATGTCCAGCAAAAGAGCAAAGGGG\
                    eGFP-myl9b-for                                                                                                                  AAGACC

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CGCCCTTGCTCACCATGTCGTCTTTGT\
  DNA reagent       PG1-flk-MCS-tol2-myl9b-\                                                                                                        CTTTGGCTCCGTGTTT
                    eGFP-myl9b-rev                                                                                                                  

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CAAAGACGACATGGTGAGCAAGGGCG\
  DNA reagent       PG1-flk-MCS-tol2-myl9b-\                                                                                                        AGGAGCTGTTCACCGGG
                    eGFP-eGFP-for                                                                                                                   

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GGATCCGATATCCTCGAGGGTACCG\
  DNA reagent       PG1-flk-MCS-tol2-myl9b-\                                                                                                        TTATCTAGATCCGGTGGATCCCG\
                    eGFP-eGFP-rev                                                                                                                   GGCCCGC

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           ATCCCGCGGTGGAGCTCCAGAATTCAT\
  DNA reagent       pTol2-Runx1 + 23-betaglobin-\                                                                                                   GTCTGCAGCCAAACGCGCCAAAGG
                    myl9a-mKate2-myl9a-for                                                                                                          

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GCATGTTCTCCTTAATCAGCTCGCTC\
  DNA reagent       pTol2-Runx1 + 23-betaglobin-\                                                                                                   ACCATGTCGTCCTTGTCTTTGGCTCC
                    myl9a-mKate2-myl9a-rev                                                                                                          

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GAGCCAAAGACAAGGACGACATGGT\
  DNA reagent       pTol2-Runx1 + 23-betaglobin-\                                                                                                   GAGCGAGCTGATTAAGGAGAACATGC
                    myl9a-mKate2-mKate2-for                                                                                                         

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           GGATCCGATATCCTCGAGGGTACCGTC\
  DNA reagent       pTol2-Runx1 + 23-betaglobin-\                                                                                                   ATCTGTGCCCCAGTTTGCTAGGG
                    myl9a-mKate2-mKate2-rev                                                                                                         

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CAGACATCCCGCGGTGGAGCTCC\
  DNA reagent       pTol2-Runx1 + 23×1-\                                                                                                            AGGTCGCCACCATGTCCAGCAAAAG\
                    betaglobin-myl9b-eGFP-\                                                                                                         AGCAAAGGGGAAGACCACCAAG
                    myl9a-for                                                                                                                       

  Recombinant\      Oligo for Cloning:\                This paper                     N/A                                                           CGCCCTTGCTCACCATggtggcgacGAA\
  DNA reagent       pTol2-Runx1 + 23×1-\                                                                                                            TTCCATGTCGTCTTTGTCTTTGG\
                    betaglobin-myl9b-eGFP-\                                                                                                         CTCCGTG
                    myl9a-rev                                                                                                                       

  Recombinant\      Oligos for mutagenesis:\           This paper                     N/A                                                           CAGACATCCCGCGGTGGAGCTCCA\
  DNA reagent       pTol2-Runx1 + 23×1-\                                                                                                            GgtcgccaccAtggccgccaaaagagca\
                    betaglobin-myl9b-eGFP-\                                                                                                         aaggggaagaccaccaag
                    myl9aA2A3-for                                                                                                                   

  Recombinant\      Oligo for mutagenesis:\            This paper                     N/A                                                           CGCCCTTGCTCACCATggtggcgac\
  DNA reagent       pTol2-Runx1 + 23×1\                                                                                                             GAATTCcatgtcgtctttgtctttg\
                    betaglobin- myl9b-eGFP-\                                                                                                        gctccgtg
                    \                                                                                                                               
                    myl9aA2A3-rev                                                                                                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Contact for reagent and resource sharing {#s4-1}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding Authors, Anne A. Schmidt (anne.schmidt\@pasteur.fr) and Philippe Herbomel (philippe.herbomel\@pasteur.fr).

Zebrafish husbandry {#s4-2}
-------------------

Zebrafish (*Danio rerio*) of the AB background and transgenic fish carrying the following transgenes *Tg(kdrl:HsHRAS-mCherry)*^s916 ^ ([@bib8]) also referred to as *Tg(kdrl:Ras-mCherry)*, *Tg(fli1a:Lifeact-eGFP)*^zf495^ ([@bib48]), *Tg(fli1ep:Gal4ff)*^ubs3^ ([@bib62]), *Tg(5xUAS:RFP)*^nkuasrfp1a^ ([@bib4]), *Tg(UAS:eGFP-ZO1)*^ubs5^ ([@bib20]), *Tg(kdrl:eGFP)*^s843^ ([@bib26]), *Tg(−6.0itga2b:eGFP)*^la2^ ([@bib38]) also referred to as *Tg(CD41:eGFP)*, *Tg(kdrl:Gal4; UAS:RFP), Tg(kdrl:Myl9a-eGFP)*^ip5^ and *Tg(kdrl:Myl9b-eGFP)*^ip6^ (this study) were raised and staged as previously described ([@bib28]). Fish were maintained on a 14 hr light/10 hr dark cycle, and embryos were collected and raised at 28.5 or 24°C in N-Phenylthiourea (PTU, Sigma Aldrich, Cat\#: P7629)/Volvic source water (0.003%, final) to prevent pigmentation implemented with 280 μg/L methylene blue (Sigma Aldrich, Cat\#: M4159). The embryos used were of early developmental stages (26--50 hpf), precluding sex determination of the animals. The general fish maintenance at the Institute follows the regulations of the 2010/63 UE European directives and is supervised by the veterinarian office of Myriam Mattei.

Transient and stable transgenesis {#s4-3}
---------------------------------

All constructs were generated using the Gibson Assembly method (NEB, Cat\#: E2611S). The *myl9a* and *b* sequences were amplified from a pool of cDNAs made using 24 to 48 hpf whole zebrafish embryos (see Key Resources Table for the primers used, Super Script III kit, Cat\#: 8080093 and Expand High Fidelity polymerase, Sigma Aldrich, Cat\#:11732641001). The *kdrl* promoter (*Flk*) ([@bib26]) was used to drive endothelial expression of Myl9a and Myl9b fused at their carboxy-terminus, with eGFP (Clontech) or mKate2 (Evrogen). The murine runx'1 + 23' enhancer ([@bib54]) coupled with the murine betaglobin was used to drive hemogenic expression. Final constructs were purified using the NucleoBond Xtra Midi endotoxin free kit (Macherey Nagel, Cat\#: 740420.10) and 25 ng/μl were co-injected into one-cell stage zebrafish embryos along with 25 ng/μl *tol2* transposase mRNA transcribed from linearized pCS-zT2TP ([@bib53]) plasmid using the mMESSAGE mMACHINE SP6 kit (Ambion, Cat\#: AM1340) ([@bib27]; [@bib33]). Embryos were screened for fluorescence between 24 hpf and 48 hpf, selected for imaging or raised to adulthood for stable transgenesis. Founders were isolated by screening for fluorescence. For stable transgenesis, the following plasmids have been injected: pG1-flk-MCS-tol2-Myl9a-eGFP or pG1-flk-MCS-tol2-Myl9b-eGFP. For transient transgenesis, the following plasmids have been used: pTol2-Runx1+23-1-betaglobin-myl9b-eGFP, pTol2-Runx1 + 23-1-betaglobin-myl9bA2A3-eGFP, pTol2-Runx1 + 23-1-betaglobin-Myl9a-mKate2, pUAS:eGFP-hs-ZO1.

Mutagenesis {#s4-4}
-----------

The Myl9b phosphorylation mutant form was generated by site directed mutagenesis using a sense 5-prime primer containing three nucleotide substitutions and PCR amplification using the wild-type *myl9b* cDNA as template. The sense primer also contained a Kozak sequence. Sense and anti-sense primers contained extensions for cloning the PCR product into the pTol2-Runx1+23-1-beta-globin:eGFP using the Gibson Assembly method. The double mutation was verified by sequencing.

Sense mutagenesis primer (with the substituted nucleotides in underlined bold):

CAGACATCCCGCGGTGGAGCTCCAGGTCGCCACCATG**[**G**]{.ul}**CC**[**GC**]{.ul}**CAAAAGAGCAAAGGGGAAGACCACCAAG

Reverse primer:

CGCCCTTGCTCACCATGGTGGCGACGAATTCCATGTCGTCTTTGTCTTTGGCTCCGTG

Morpholino microinjections {#s4-5}
--------------------------

Splice blocking morpholinos (MOs, see Key Resources Table for sequences), myl9aspe2i2, myl9aspi3e4, myl9bspe2i2, myl9bspe3i3, and as well as the *sih* Tnnt2 translation start codon and flanking 5-prime sequence MO ([@bib50]) were prepared in stock solutions at 2 mM in ddH~2~O. 1.5 (sih MO) or 4--12 ng (*myl9a* and *myl9b* MOs) were injected into one-cell stage zebrafish embryos. The same amount of MO targeting a mutated form of the human beta-globin pre-mRNA was used as control (Standard Control from GeneTools). Splice blocking efficiency was confirmed for each *myl9* MO using qRT-PCR assays (see Key Resources Table for sequences) and the resulting phenotypes were assessed by manual counting of CD41:eGFP-positive cells in the AGM and the CHT of 40 and 50 hpf embryos. Results obtained using the MOs myl9aspe2i2 (MO *myl9a*, 12 ng) and the MO myl9bspe3i3 (MO *myl9b*, 12 ng) are presented in [Figure 8](#fig8){ref-type="fig"}. For *sih* morphants, embryos that were imaged were checked for absence of heart beating 24 hr after injection as well as before and after experimental analysis.

Rescue experiment {#s4-6}
-----------------

Capped and poly-adenylated full-length *myl9b* mRNAs were synthesized using the mMESSAGE mMACHINE kit (Ambion, Cat\#: AM1340) and the Poly(A) Tailling kit (Ambion, Cat\#: AM1350) from *myl9b* cDNA amplified by PCR from our pG1-flk-MCS-tol2-Myl9b-eGFP expression vector. 100 or 200 pg of *myl9b* mRNA were microinjected into one-cell stage *Tg(CD41:eGFP*) embryos either alone or in combination with 6 ng or 12 ng of myl9bspe3i3 morpholino. The resulting phenotypes were assessed by manual counting of CD41:eGFP-positive cells in the AGM and the CHT of 48 and 50 hpf embryos.

Whole-mount in situ hybridization and cryosections {#s4-7}
--------------------------------------------------

Whole-mount chromogenic in situ hybridization was performed as described previously ([@bib55]). Briefly, embryos were hand dechorionated, fixed in 4% FA (Polysciences, Cat\#: 040181) overnight at 4°C and stored in 100% MeOH at −20°C. Embryos were permeabilized using 10 μg/ml Proteinase K (Ambion, Cat\#: AM2546) in PBT (1x PBS + 0.1% Tween) for 5 min and post-fixed in 4% FA for 20 min. Hybridization was performed using 200 ng Digoxigenin-labeled myl9a (RefSeq: NM_001006027) and myl9b (RefSeq: NM_213212) probes synthetized using the manufacturer recommendation (T7 RNA polymerase, Promega, Cat\#: P2075, DIG-nucleotides, Jena Bioscence, Cat\#: NU-803-DIGX). Detection of the probes was performed by incubating the embryos with an anti-Digoxigenin antibody coupled to alkaline phosphase (Roche, Cat\#: 11207733910) diluted 1:5000 in blocking solution 1X WBR (Roche, Cat\#: 11921673001). The staining reaction was performed using NBT/BCIP (Sigma, Cat\#: N6639, Cat\#: B-8503) in NTMT buffer (100 mM Tris HCl pH 9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween). Subsequently to the revelation, embryos were washed in PBT and incubated in 30% sucrose for 2 days at 4°C and with agitation before embedding in tissue freezing medium blue (Electron Microscopy Sciences, Cat\#: 72592-B) and frozen in liquid nitrogen. Transverse sectioning was performed at 5 μm using a CM 3050 cryostat (Leica) and slices were dried for 2 hr before mounted with AquaPoly Mount medium (Biovalley, Cat\#: 18606--5). Images were captured on an Olympus vs120 slide scanner using an ORCA Flash4.0 V2 CMOS camera (Hamamatsu) and a UPLSAPO 20X objective (Olympus).

Quantitative real-time PCR {#s4-8}
--------------------------

To determine the splice-blocking efficiency of *myl9a* and *myl9b* MOs, cDNA was extracted from 20 whole 48 hpf embryos and qRT-PCR oligos were designed to hybridize on the joined sequential exons initially surrounding the splicing sites targeted by the MOs (see Key Resources Table for sequences). One-cell-stage embryos were injected with 4--8 ng of *myl9a* or *myl9b* or Standard control MOs (see Key Resources Table for sequences) and raised until 48 hpf. Total mRNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Cat\#: 74134) as indicated by the manufacturer and the concentration was obtained by nanodrop quantification (Nanodrop1000, ThermoFisher). Equivalent amounts of RNA (300 ng) were used as template for cDNA synthesis, which was performed using the M-MLV Reverse Transcriptase kit (Invitrogen, Cat\#: 28025013). qRT-PCR was performed using Takyon Rox SYBR Master mix blue dTTP kit (Eurogentec, Cat\#: UF-RSMT-B0701), 15 ng of cDNA and 10pM of each primer. qRT-PCR was carried out for three biological replicates with measurements taken from three technical replicates on an Applied Biosystems 7300 Real Time PCR system (Thermofisher). The relative expressions of *myl9a* and *9b* were determined after normalization to zebrafish elongation factor 1a (*eif1*α). The conditions from the samples injected with the *myl9* MOs were compared to the Control ones using the delta-delta-Ct method. To determine the potential off target effect of *myl9a* MOs on *myl9b* expression and of *myl9b* MOs on *myl9a* expression (see Key Resources Table for oligo sequences), RNA extraction was performed as described above; cDNA synthesis was performed using the SuperScript III kit (ThermoFisher, Cat\#: 8080093), equivalent amount of RNA (200ng) and qRT-PCR were performed as described above. The graph presented in [Figure 8---figure supplement 1D](#fig8s1){ref-type="fig"} corresponds to two independent experiments carried out in triplicates. Due to the low n number (n = 2), this graph indicates a tendency.

Embryo mounting for confocal imaging {#s4-9}
------------------------------------

Embryos were hand dechorionated and anesthesized using tricaine (Sigma Aldrich, Cat\#: A5040). Then, they were mounted in lateral position and embedded in 1% low melting agarose (Promega, Cat\#: V2111) in a glass-bottom μ-Dish (Ibidi, Cat\#: 81158). To avoid movements and pigmentation during image acquisitions, 1x tricaine/1 x PTU Volvic water was incorporated to the low melting agarose and, after solidification, added on top of it.

In vivo spinning-disk confocal imaging {#s4-10}
--------------------------------------

Embryos were imaged on an inverted microscope (UltraVIEW VOX, Perkin Elmer) equipped with a Yokogawa CSU-X1 spinning-disk, an ImagEM-X2 camera (Hamamatsu), 488 nm and 561 nm laser lines for excitation, a Zeiss LD C-Apochromat 40x corrM27 water objective (NA 1.1, WD 0.62 mm at cover glass 0.17 μm) and the Volocity (Perkin Elmer, <http://www.perkinelmer.com/>) acquisition software. Optical Z planes were spaced by 0.6 μm, the power of the lasers (around 150 mW) and exposure time (between 50 ms and 200 ms) were adjusted depending on the fluorophore and the transgenic line used. In all cases, acquisitions of a Z stacks containing the whole dorsal aorta was reduced to 1 min or less and spaced every 2 min. For TL sequences longer than 1 hr, samples were maintained at 28.5°C using an Okolab cage incubator and the objective was immersed in Immersol W 2010 oil (Zeiss, Cat\#: 444969-0000-000).

In vivo laser scanning confocal imaging {#s4-11}
---------------------------------------

Embryos were imaged using an inverted microscope (Leica TCS SP8, CTR 6500), equipped with 488 nm and 561 nm diodes for excitation, a Hybrid Detector, a Leica HC PL APO CS2 40x water objective (NA 1.1, WD 0.65 mm at cover glass 0.17 μm) and the LAS X acquisition software (Leica, <http://www.Leica-microsystems.com>). Optical planes were spaced by 0.43 μm and Z stacks containing the whole dorsal aorta were acquired every 5-10 min. For long time-lapse imaging, samples were maintained at 28°C using a INU stage Top Incubator (Tokai Hit) and the objective was immersed in 1:1 AquaSound Clear (Free-med, Cat\#: FU00071) ultrasound gel with water. For cell counting in live embryos, an HC PL APO CS2 20x IMM objective (NA 0.75, WD 0.67 mm) and a resonant scanner were used for high-speed imaging of the whole AGM or CHT. Subsequent maximum projection and manual counting was performed.

Some embryos were imaged with an upright microscope (Leica SPE, CTR 6000), equipped with 488 nm and 532 nm diodes for excitation, an immersion HCX APO LUV-I 40x water objective (NA 0.8, WD 3.3 mm) and the LAS AF version 2.6.0.7266 acquisition software (Leica). Optical planes were spaced by 0.6 μm and Z stacks containing the whole dorsal aorta were acquired every 5 min.

AortaTracker algorithm for 2D projections {#s4-12}
-----------------------------------------

The algorithm developed for the projection of the aortic wall on a 2D plane, using fluorescent signals, was called AortaTracker. It is decomposed in two sections aimed at (1) the segmentation of the aortic tube, (2) the unwrapping. To perform the segmentation of the tube, the algorithm first needs to be initialized by the user. To circumvent the variations in the aortic shape, movements, and signals coming from neighboring structures, a strong constrained surface is imposed to the aortic wall (this part is available as an Icy plugin (<http://icy.bioimageanalysis.org>) called TubeSkinner; \[[@bib11]\]). The aorta tube is rotated so that its axis becomes almost aligned with the Z-axis. On the first Z-section, the user then manually adjusts a circle fitting the inner part of the aorta. In such a section, the aorta is represented as a few numbers of bright spots representing the intersection of the plane with cellular membranes. The circle is then adjusted to maximize the sum of the fluorescent signals in a crown around its diameter, and to minimize the sum of intensity inside the inner circle of the crown. This procedure is repeated along the tube, effectively locating its central axis. Then for each circle, the intensity is collected along its perimeter as the maximal signal in the crown for a given angle. Finally, the unwrapper algorithm creates the image by transforming the point in the z-stack to the (theta, r) coordinate system considering the circle fit, making sure the final calibration is isotropic. No interpolation is performed on pixel intensity. The X-axis of the final image corresponds to the perimeter of the circles, and its Y-axis corresponds to the tube central axis.

2D-Maps representation {#s4-13}
----------------------

The obtained 2D-maps were then duplicated to merge the rims of unwrapped aorta and visualize the continuity of all cell contours.

3D-rendering {#s4-14}
------------

3D-rendering of live-imaging have been processed using the Imaris software (Bitplane, <http://www.bitplane.com/>).

Manual A-P distance measurements {#s4-15}
--------------------------------

We considered the Antero-Posterior luminal distance (A-P distance), as the length between the most anterior and posterior luminal poles of the EHT undergoing cell, aligned with the A-P axis.

In the case of EHT cells emerging parallel to the A-P axis, we used the 'Straight Line' tool on Fiji software (NIH, <https://imagej.net/Fiji>) and measured the A-P distance (for each time points in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) on 2 or three consecutive Z-planes localized in the central part of the EHT cell (where the apparent A-P distance was the longest) and averaged.

For cells emerging at a small angle relative to the A-P axis, we measured the apparent A-P distance on the maximum projection along the Z-axis; when the angle was larger, we first performed a 3D-rotation on Imaris software so as to align the cell in the X-Y plane before doing the measurement.

Semi-automatic A-P distance and closing speed measurements {#s4-16}
----------------------------------------------------------

In order to measure A-P luminal distances and dynamics ([Figure 2](#fig2){ref-type="fig"}), dense eGFP-ZO1 extremities were independently tracked using the Fiji plugin TrackMate ([@bib56], <https://imagej.net/TrackMate>) after maximum projection along the Z-axis and X,Y translation using the Fiji plugin 'Descriptor based series registration' to correct the X,Y drift ([@bib49]). Tracks display and subsequent distance analysis were performed using the MATLAB software (MATLAB 2017a, , The MathWorks, <https://fr.mathworks.com>). To focus on long scale activity rather than short displacements, the distance between the two extremities was filtered twice using an unweighted sliding-average over 20 min. Following this process, we characterized the speed at which the A-P luminal distance decreases by automatically extracting the closing speed local minima and filtering them based on their prominence (\>0.01 µm/min). For additional details see [https://fr.mathworks.com/help/matlab/ref/islocalmin.htm[l]{.ul}.](https://fr.mathworks.com/help/matlab/ref/islocalmin.html.) Distance between successive minima was used to measure the acceleration-deceleration cycle duration distribution (for the algorithm and codes in MATLAB (version 2017b), see the link: <https://github.com/sebherbert/EHT-analysis> ([@bib19]; copy archived at <https://github.com/elifesciences-publications/EHT-analysis>).

Tracks length {#s4-17}
-------------

Distances in x were measured between the most anterior and posterior positions of the tracks.

Morphometric analysis of aortic cells using 2D-maps {#s4-18}
---------------------------------------------------

Cells were manually delimited using the 'Polygon Selections' tool on Fiji software and areas directly extracted from the measurement tool in Fiji. The length (parallel of the blood flow axis) and width (along the circumference of the aortic wall) were extracted from the rectangle that best fits the cell.

Aortic cell types specification {#s4-19}
-------------------------------

To classify the aortic cells in one category or another (endothelial, potentially hemogenic or EHT cell, see [Figure 4](#fig4){ref-type="fig"}), we defined a series of criteria that take into account their respective length (along the antero-posterior axis), width (along the circumference of the aortic wall) and positioning in regard to the medio-lateral axis. By looking through the Z-planes and selecting the one for which the aorta is of the largest diameter in the dorso-ventral axis, we first determined the ventral floor axis and placed it on the 2D-map (see Floor on the maps). The roof (see Roof on the maps) was subsequently positioned at a distance corresponding to half the length of the unwrapped aorta (allowing to determine the surfaces of the frontside and backside). We then applied a relatively stringent cut-off and considered that the pseudo-hemogenic cell category did not extend beyond the medio-lateral axis of the aorta while spanning the ventral floor.

Number of neighboring cells {#s4-20}
---------------------------

Cells were considered as neighbors when at least a part of their lateral junctions were in direct contact.

Statistical analysis {#s4-21}
--------------------

Statistical analysis was performed using Student unpaired t test with Welch's correction (does not assume similar SD) in GraphPad Prism six software (<https://www.graphpad.com/>). Graphs depict Mean ± SEM or SD or median alone and differences with p value ≤ 0.05 (\*) were considered statistically significant.

Data and software availability {#s4-22}
------------------------------

The AortaTracker algorithm for 2D projections is available as an Icy plugin (<http://icy.bioimageanalysis.org>).
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Decision letter

Zon

Leonard I

Reviewing Editor

Boston Children\'s Hospital

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Anisotropic organization of circumferential actomyosin characterizes hematopoietic stem cells emergence in the zebrafish\" for consideration by *eLife*. Your article has been reviewed by Sean Morrison as the Senior Editor, a Reviewing Editor, and two reviewers. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The work nicely defines imaging of the EHT that is important for stem cell production, and the physical actions that must happen for the budding of stem cells.

Essential revisions:

For the rebuttal, please pay attention to the timing issues addressed in reviewer 1, point number 1. Both reviewers had issues with the myl9b morpholino work, as illustrated by point 2 of reviewer 1 and point 1 of reviewer 2. Blood flow should also be addressed as reviewer 2\'s point 2. That could be accomplished by the silent heart morpholino or using chemicals.

*Reviewer \#1:*

The submitted work by Schmidt et al. builds upon previous work from the Herbomel lab (Kissa and Herbomel, 2010) studying the hematopoietic stem cell (HSC) endothelial to hematopoietic transition (EHT) in zebrafish. The present study uses novel imaging techniques and software analysis to investigate the biomechanics of this process. Based on their data, the authors come to three major conclusions: (i) EHT involves anisotropic contraction along the anterior-posterior (AP) axis facilitated by the heterogeneous organization of contractile circumferential actomyosin, (ii) the contraction is oscillatory with periods of stability that are much longer than other known cell extrusion processes, and (iii) *myl9b* is a target of Runx1 and its amino-terminal phosphorylation site is critical to definitive hematopoiesis. Overall, although the writing could be more clear and succinct and conclusion (ii) could be better supported with requested data and information, this submission provides new and valuable insights into the EHT and seems to be a good fit for publication in *eLife* pending revisions.

1\) Conclusion (ii) would be better supported by an improved and more standardized approach to determining length of time of the EHT. This could include more specific and quantitative definitions of the intervals that the authors refer to as \"periods\" and \"pseudo-plateaus.\" Using time of imaging onset does not appear to be the best initial time from which to measure the duration of the EHT since it is somewhat arbitrary -- can this be more standardized from the data already collected? Further, the description for calculating oscillation duration and stabilization was vague, and it was not clear from the text which parameters the authors used to define acceleration/deceleration cycles. And, why were only 7 tracings shown in Figure 1---figure supplement 1C? These tracings don\'t appear to incorporate the full range of closing patterns observed nor does the 2-4 μm cut-off seem to apply more broadly (e.g., see Figure 2C). Finally, the authors could do a better job comparing (both qualitatively and quantitatively) their findings for EHT to other cell extrusion processes in the Discussion to strengthen their argument for the uniqueness of the EHT and to situate their findings in a broader context.

2\) With regard to conclusion (iii), although the authors demonstrate what they claim as a major conclusion, their data leave open a few questions that would be good to address in this work in accordance with published standards for morpholinos (see Stainier et al., 2017). This could include phenocopies with multiple morpholinos or rescue experiments. Could the *myl9a* data (i.e., not regulated by Runx1 but affecting hematopoiesis) be explained by an off-target effect of the morpholino on *myl9b*? What would *myl9b* expression look like with the myl9a morpholinos (potentially add condition to Figure 6---figure supplement 1E)? What does the dose response curve look like and why were such high quantities of morpholinos injected (8-12ng) in the main text when Figure 6---figure supplement 1E suggests that 4ng gave similar changes in mRNA expression levels? Do the myl9aspe2i2 and myl9bspe2i2 morpholinos phenocopy myl9aspi3e4 and myl9bspe3i3, respectively?

*Reviewer \#2:*

In this manuscript, the authors described the detail process of endothelial-hematopoietic transition (EHT) including EHT time consumption and occurrence location, hemogenic endothelium morphological change, and dynamic change of intercellular cell junction and cytoskeleton. They regarded EHT as a special pattern of developmental morphogenetic event and cell extrusion. Finally, the authors showed that *myl9b* is a downstream target of Runx1 and plays a role in the dynamic change of cytoskeleton during EHT. Although this is a nice piece of cell biology work, the genetic regulation analysis is relatively rough and weak. It also lacks mechanistic study to explore the signals that trigger the dynamic change of hemogenic endothelium. Addition of these data will significantly enhance the quality of the manuscript.

1\) In subsection "Hemodynamic forces control the morphodynamics of the emergence" and Figure 6, the authors argued that Runx1 positively regulates the expression of *myl9b*. Because MO knockdown may have toxicity and off-target effects, the authors should re-examine the expression pattern of *myl9b* in *runx1* mutants rather than *runx1* morphants. More importantly, time-lapse imaging should be performed on *runx1* mutants to find out whether the patterns of Myl9b and F-actin are indeed perturbed in hemogenic endothelium in the mutant fish. Finally, CHIP assay should also be performed to confirm Runx1 indeed binds to the promoter or enhancer of the *myl9b* gene and promotes the expression of *myl9b* in zebrafish.

2\) The authors showed that during the EHT, ZO1 and F-actin tend to be enriched in the trijunctions and membrane interfaces that are perpendicular to the blood flow, raising the possibility that blood flow may act as an extracellular mechanical force that triggers or affects the morphological change and cytoskeleton dynamics of HE during EHT. Thus, it would be of great interest to investigate the influence of blood flow on EHT dynamics by manipulating the physical property of blood flow (velocity, volume and viscosity, for example).

10.7554/eLife.37355.043

Author response

> Essential revisions:
>
> For the rebuttal, please pay attention to the timing issues addressed in reviewer 1, point number 1.

We have reinvestigated our time-lapse experiments and found 7 EHT cells that were imaged, starting from a flat morphology (hemogenic cells) to their exit (hence including the cup shape stage). We observed that, as is the case for the time-to-exit of cells imaged starting at the cup shape stage, the time intervals between the flat morphology to the cup shape stage are also very variable, with an average of 6.5 hours (ranging from 3.2 hours to 10.33 hours). We have now calculated the apparent complete duration of the EHT, which lasts for more than 10 hours on average (apparent because it is currently impossible to determine the precise starting point at which EHT committed cells, in the hemogenic endothelium, will initiate the emergence). This very long timing of the process reinforces the fact that starting imaging when hemogenic cells committed to perform the EHT are still flat is at risk regarding phototoxicity (which legitimates our initial choice of imaging the process starting at the cup shaped stage). These results are included now in a new version of Figure 1---figure supplement 1, panels A and B (left part), the new Figure 1---video 3 and the related paragraph in the revised main text.

> Reviewers had issues with the myl9b morpholino work, as illustrated by point 2 of reviewer 1 and point 1 of reviewer 2.

We have performed 3 major sets of experiments with respect to these concerns, which are outlined in more detail in response to reviewer 1 point 2.

> Blood flow should also be addressed as reviewer 2\'s point 2. That could be accomplished by the silent heart morpholino or using chemicals.

We have performed experiments using a silent heart morpholino and show/illustrate a series of results, with details given in response to reviewer 2's point 2.

Reviewer \#1:

> \[...\] 1) Conclusion (ii) would be better supported by an improved and more standardized approach to determining length of time of the EHT. This could include more specific and quantitative definitions of the intervals that the authors refer to as \"periods\" and \"pseudo-plateaus.\" Using time of imaging onset does not appear to be the best initial time from which to measure the duration of the EHT since it is somewhat arbitrary -- can this be more standardized from the data already collected? Further, the description for calculating oscillation duration and stabilization was vague, and it was not clear from the text which parameters the authors used to define acceleration/deceleration cycles. And, why were only 7 tracings shown in Figure 1---figure supplement 1C? These tracings don\'t appear to incorporate the full range of closing patterns observed nor does the 2-4 μm cut-off seem to apply more broadly (e.g., see Figure 2C). Finally, the authors could do a better job comparing (both qualitatively and quantitatively) their findings for EHT to other cell extrusion processes in the Discussion to strengthen their argument for the uniqueness of the EHT and to situate their findings in a broader context.

First of all, we wish to thank the reviewer for his/her fruitful recommendations and critics, in particular the ones on (i) the duration of the EHT (and the matching between the temporal evolution of the process and the phases of contraction and stabilization) and (ii) the morpholino work. In addition, and regarding the main text, we believe that things are more clearly explained now and that the text gained very much in quality following the reviewer's recommendations.

Please find beneath our answers to the specific points.

Regarding the duration of the EHT, we have provided a response to this in the first point in the Essential revisions section of the decision letter.

Regarding the 2-4 μm cut-off, we agree that this does not apply to all cells and have simplified the text accordingly and propose (subsection "EHT dynamics at high spatio-temporal resolution"):

"Secondly, we noticed that the narrowing down of the A-P luminal distance did not occur at a uniform pace, but with phases of contraction and of relative stabilization of variable durations taking place in the limit of an A-P luminal distance of approximately 2 µm, followed by steep decrease until the release of the cell (this fast drop may represent a collapse following the culmination of mechanical tensions). Hence, the heterogeneous duration of the EHT might be explained by these discontinuities, the reasons of which being unknown."

Regarding the biomechanics of the apical constriction, we have improved the main text so as to describe more clearly the phases of contraction, relative stabilization and oscillations (phases of acceleration/deceleration). As a support to the main text, we have made a new supplemental figure that clearly indicates what we refer to as contraction, stabilization, period and pseudo-plateau (see the new Figure ---figure supplement 1 and its legend). The text that we now propose is found in subsection "Intercellular junctions and apical constriction of EHT cells are anisotropic".

In addition, following the reviewer's requests, we have improved the quantitative analysis of some of the parameters of the apical contraction and automatized the mathematical analysis of the oscillation periods:

a\) For the calculation of the periods, we have automatized the analysis by using a small algorithm based on the prominence (the prominence of a local minimum, or valley, measures how the valley stands out with respect to its depth and location relative to other valleys), see the following link that we have also indicated in a revised paragraph in Materials and methods section, in which one can find also the information for the algorithm): https://fr.mathworks.com/help/matlab/ref/islocalmin.html

b\) The calculation of the periods is what is the most important here hence we have not automatized the calculation of the pseudo-plateaus and removed this information from the plot Figure 2D.

Figure 1C shows only 7 tracing because all measurements were performed by hand, which was extremely fastidious (in comparison to the A-P distances measured and reported Figure 2C that were obtained semi-automatically using TrackMate and are more resolutive (because less noisy)). Showing those data in the Supplement file and at that stage of the paper allows introducing, with the support of a morphological criterion, the reason why the EHT process is stochastic and variable in time.

We are astonished to read this comment 'the authors could do a better job comparing (both qualitatively and quantitatively) their findings for EHT to other cell extrusion processes in the Discussion section'. Indeed, we make quantitative comparisons in the Discussion section, but we focused on few cases (among which 1 extrusion case), the reason being that those have been the most extensively characterized and quantified (ventral cells in *Drosophila* and the ingression of neuroblasts, also in *Drosophila*). In addition, we feel that this would rather be the scope of a review on the topic. We have substantiated with few additional numbers the part regarding the oscillations.

> 2\) With regard to conclusion (iii), although the authors demonstrate what they claim as a major conclusion, their data leave open a few questions that would be good to address in this work in accordance with published standards for morpholinos (see Stainier et al., 2017). This could include phenocopies with multiple morpholinos or rescue experiments. Could the myl9a data (i.e., not regulated by Runx1 but affecting hematopoiesis) be explained by an off-target effect of the morpholino on myl9b? What would myl9b expression look like with the myl9a morpholinos (potentially add condition to Figure 6---figure supplement 1E)? What does the dose response curve look like and why were such high quantities of morpholinos injected (8-12ng) in the main text when Figure 6---figure supplement 1E suggests that 4ng gave similar changes in mRNA expression levels? Do the myl9aspe2i2 and myl9bspe2i2 morpholinos phenocopy myl9aspi3e4 and myl9bspe3i3, respectively?

With regard to the Myl9a and Myl9b morpholinos work, we have performed 3 major sets of experiments with the following outcomes:

We have addressed the potential off-target effect of Myl9a morpholinos on Myl9b mRNAs and vice versa: 3 independent experiments of qRT-PCR were performed addressing the expression levels of each mRNAs upon injection of all different morpholinos independently. In summary, neither Myl9a nor Myl9b morpholinos triggered significant off-target effects. However, with one of the Myl9a morpholinos (spi3e4), we measured an increase in the Myl9b mRNAs indicating that decreasing Myl9a expression can trigger a compensatory response on Myl9b mRNA expression.

These results, more complete, are now substituting the previous results of the previous Figure 6---figure supplement 1, now becoming Figure 8---figure supplement 1.

In addition, because the phenotype triggered by the use of the Myl9a morpholino spi3e4 may be owed to a compensatory response by the upregulation of Myl9b, the left panels of the new Figure 8D and E (previous Figure 6E and F) are now composed with data obtained with the second Myl9a morpholino (spe2i2).

We have phenocopied the phenotype (on the number of CD41:eGFP+ cells in the CHT and sub-aortic space) with a second morpholino for both Myl9a and Myl9b and provide dose-dependences of the effects of morpholinos on the numbers of CD41:eGFP+ cells. The results are now composing part of a new supplemental figure (that is now Figure 8---figure supplement 2A).

We have rescued the sub-aortic and CHT phenotypes triggered by Myl9b (spe3i3) morpholinos (number of CD41:eGFP+ cells in the sub-aortic region and the CHT) by injecting Myl9b encoding mRNAs.

The results are now composing part of the new Figure 8---figure supplement 2B.

Finally, we also addressed particular points in regard to the experiments aimed at interfering with the activity of the Runx1 transcription factor and analysing consequences on Myl9a and Myl9b mRNAs expression (by another approach than using morpholinos).

As the reviewer will see below, we have conducted two other approaches that gave opposite results than the morpholino approach, i.e an increase in Myl9b mRNAs upon decreasing Runx1 expression.

For the entire issue regarding the interference with Runx1, we have prepared 3 figures ([Author response image 1](#respfig1){ref-type="fig"}, [Author response image 2](#respfig2){ref-type="fig"} and [Author response image 3](#respfig3){ref-type="fig"}).

[Author response image 1](#respfig1){ref-type="fig"} recapitulates the Runx1 morpholino work, with the qRT-PCR work (panel B of initial Figure 6), as well as a graph (E) on the dose-dependence of the effects triggered by the morpholino on the number of hematopietic cells in the CHT (with a maximum of approx. 50% decrease in the expression of Runx1 mRNAs at 10ng (D)). This makes the point on why we used such a high concentration (10ng, for the panel B of initial Figure 6).

![Runx1 morpholino analysis.\
This figure shows the several experiments that were performed to characterize the runx1 morpholino that was used in this study (first submission). The panel C was originally in the previous Figure 6B. Panels A and B were originally in Figure 6---figure Supplement 1. A and B show the localization of myl9a and myl9b qPCR oligos and amplified products.](elife-37355-resp-fig1){#respfig1}

\(C\) qPCR analysis after inhibition of the EHT by injections of runx1 morpholinos. The schematic drawing indicates that only the posterior part of 48 hpf embryos were used for the qPCR (n=2 independent experiments, in triplicates). Relative expression of genes expressed after injection of control or runx1 morpholinos. Error bars represent mean values ± SEM. unpaired t test (\*\*\*\*) p\<0.0001.

\(D\) Level of Runx1 mRNA expression after injections of 4, 8 and 10 ng of morpholino. Note that the choice of the 10 ng in the qRT-PCR experiment was because 4 and 8 ng were not sufficient to reach at least 50% reduction in Runx1 mRNAs. This correlates with the data on the phenotype panel E.

\(E\) Quantification of runx1:nls-mCherry+ cells (Runx1+23 enhancer) in the CHT of 48hpf embryos after 4-12 ng morpholino. Note that the significant reduction in numbers starts at 10ng.

\(F\) Visualization of the phenotype in embryos at 48hpf; right: CHT..\</[Author response image 1](#respfig1){ref-type="fig"} title/legend\>

[Author response image 2](#respfig2){ref-type="fig"} shows the results of the transient CRISPR/Cas9 approach. This makes the point on the decrease of Myl9b mRNA expression when the mutagenesis is performed virtually at saturation.

![Analysis of Myl9b and Myl9a expression after deletion of part of the Runx1 sequence encoded by exon 4 (Runx1 crispants).\
This is the first of the 2 strategies that we have used to challenge the phenotypes obtained using the Runx1 morpholino.](elife-37355-resp-fig2){#respfig2}

\(A\) schematic representation of the localization of the 2 guides that were used, inside and flanking the 3-prime of exon 4 targeted for CRISPR/Cas9 mutation/deletion.

\(B\) The table is a list of the different indels obtained after the injection of the couple of guides together with the Cas9. DNA was extracted from 20 embryos heads corresponding to the embryos used to perform the qRT-PCRs in (C). DNA was used as template for PCR, PCR products subsequently migrated on agarose gel, and 2 bands of high and lower MW were obtained. DNA was extracted from both bands, cloned and sequenced. The first 12 lines of the table correspond to clones obtained with the material from the top band and the last line summarizes the 12 clones obtained with the material from the lower MW band and that have the entire expected deletion.

\(C\) 2 independent qRT-PCR reactions obtained from 2 independent injections. Note that sequencing showed that for the results in the top panel, the mutagenesis was performed virtually at saturation and corresponds to the sequences described in (B). Note that the qRT-PCR results for Runx1 shows the efficiency of exon 4 partial deletion. The amplicons are in the vast majority bearing harmful mutations as shown in panel B. Red bars correspond to mean values ± SD.

*Conclusion: for both experiments myl9b is increased and myl9a is not or slightly increased*. \</[Author response image 2](#respfig2){ref-type="fig"} title/legend\>

[Author response image 3](#respfig3){ref-type="fig"} shows the results for the Runx1 deletion mutation approach. This also makes the point on the decrease of Myl9b mRNA expression upon expression of the Runx1 deleted form.

![Analysis of Myl9b and Myl9a expression after expression of a deleted form of Runx1.](elife-37355-resp-fig3){#respfig3}

This is the second of the 2 strategies that we have used to challenge the phenotypes obtained using the Runx1 morpholino.

In this strategy, the idea was to inject an mRNA encoding for a deletion mutant of Runx1 (del-Runx1) that contains the runt domain and the flanking putative nuclear localization signal.

\(A\) Schematic representation of the correspondence between exons and protein domains of Runx1, with the full length form (top) and the deletion mutant (bottom).

\(B\) Quantification of CD41:eGFP+ cells after injection of 100 pg and 200 pg of del-Runx1 mRNAs in the AGM (left:top) and the CHT (left:bottom). Right panels, visualization of the phenotypes in AGM and CHT. This result validated partially the approach of the interference upon expression of del-Runx1.

\(C\) 2 independent qRT-PCR reactions obtained from 2 independent injections at 35hpf (top panel) and 48hpf (bottom panel). Note that the absence of increase in Runx1 level at 35 hpf indicates that the mRNA encoding for del-Runx1 was probably already degraded and that the decrease at 48 hpf may indicate that del-Runx1 destabilizes the endogenous mRNA. Red bars correspond to mean values ± SD.

*Conclusion: for both experiments myl9b is increased and myl9a is not or slightly increased*.\</[Author response image 3](#respfig3){ref-type="fig"} title/legend\>

For interfering with the activity of Runx1 and analysing consequences on Myl9a and Myl9b mRNAs expression, we used 2 approaches (i) transient CRISPR/Cas9 (generation of crispants, see (Burger et al., 2016)), (ii) expression of a truncated form of Runx1 deleted of the transactivation domain (supposedly a dominant-negative form, as characterized previously (Tracey et al., 1998)).

Here are the experiments that we have performed (2 sets of experiments):

To obtain the crispants, we used 1 couple of guides hybridizing in or downstream the sequence of exon 4 of the zebrafish runx1 gene (the exon that encodes for the most distal part of the runt domain that contains the essential amino acid residues involved in DNA binding). 2 independent injections were performed (each with 2 independent qRT-PCR analysis including measurements of Runx1 exon 4 deletion efficiency, expression levels of Myb (internal control), Myl9a and Myl9b mRNAs), with 1 experiment performed virtually at saturation.

In these conditions, we measured reproducibly and by qRT-PCR, small decrease for the positive control (Myb), no to little variation in Myl9a mRNAs, and a reproducible increase in Myl9b mRNAs.

We designed a potential dominant negative form of Runx1 (that is deleted of the transactivation domain and remains with the runt-DNA and CBFβ interaction domain and, in addition, a flanking downstream sequence that encompasses a putative nuclear targeting signal, i.e a mutant form that retains amino-acids 1-238. A similar deletion mutant (but lacking the putative nuclear targeting signal) was used and characterized as a dominant negative form in *Xenopus* (see Tracey et al., 1998).

Injection of mRNAs encoding for this mutant form triggered quite significant decrease of CD41:eGFP+ hematopoietic cells in the CHT at 48hpf (in addition to small haemorrhaging within the brain and, apparently, the pericardial space, which appears to be consistent with the phenotype obtained with Runx1 deficient mouse embryos (Okuda et al., 1996; Wang et al., 1996)). This validated the approach and encouraged us investigating further the effect of the Runx1 deletion mutant on the expression levels of Myl9a, Myl9b and Myb (the control). We found, for Myl9a and Myl9b approximately the same results as for the crispants: no to little variation in Myl9a mRNAs, a reproducible increase in Myl9b mRNAs, but no decrease in the positive control (Myb).

In conclusion, these 2 sets of data are contradicting the results obtained by the Runx1 morpholino approach, i.e. a potential involvement of Runx1 in controlling positively the expression of Myl9b. A possible explanation for the discrepancies, outside from toxic and/or off-target effects of morpholinos, is the activation of compensatory responses upon strong modification of Runx1 expression level that affect the consistency of results as well as the sensitivity of hemogenic cells to Runx1 dosage.

Because of these inconsistencies, we removed the results obtained with the Runx1 morpholino (which was previous Figure 6, panel B). We believe that this does not impairs the impact of this work that is now very much substantiated by the outcome of the new investigations that we have conducted on the influence of blood flow on the EHT dynamics.

Reviewer \#2:

> \[...\] 1) In subsection "Myosin regulatory light chains 9a and 9b are required for definitive hematopoiesise" and Figure 6, the authors argued that Runx1 positively regulates the expression of myl9b. Because MO knockdown may have toxicity and off-target effects, the authors should re-examine the expression pattern of myl9b in runx1 mutants rather than runx1 morphants. More importantly, time-lapse imaging should be performed on runx1 mutants to find out whether the patterns of Myl9b and F-actin are indeed perturbed in hemogenic endothelium in the mutant fish. Finally, CHIP assay should also performed to confirm Runx1 indeed binds to the promoter or enhancer of the myl9b gene and promotes the expression of myl9b in zebrafish.

First of all, we wish to thank the reviewer for his/her very fruitful recommendation on investigating the influence of blood flow on the EHT dynamics. As the reviewer will see, the outcome of the experiments is very interesting and substantiates very much the idea that blood flow has an influence on several aspects of the EHT biomechanics. In addition, the comments on the morpholinos work has been very valuable also and led to substantial revision of our work. Please find beneath our answers to the specific points.

We agree with the reviewer that we have not shown that the *myl9b* gene is a direct target of Runx1 (which we wrote was a possibility since it was shown to be the case for mouse cells). This would require, as suggested by the reviewer, a CHIP assay. The CHIP assay is the only experiment that we have not performed because we do not handle this technique in the laboratory and, taking information from other laboratories on our campus, this kind of experiment cannot reasonably be conducted in 2 months (the time we were given with this revision for which virtually all points raised by the reviewers were addressed). Importantly, and as the reviewer will see beneath, since the new experiments that were performed during this revision in order to interfere with the expression of Runx1 (using CRISPR/Cas9 and the expression of a deleted form of Runx1) gave inconsistent results with the morpholinos, we have removed the qRT-PCR data on Runx1/Myl9b, Myl9a from the paper. We believe that this does not harm the overall outcome of our work that is now more substantiated on its main message, i.e the importance of mechanical forces of the blood flow in the biomechanics of the EHT, which is a new part of the revised version and which arose after the very constructive suggestion of the reviewer.

We addressed particular points in regard to the experiments aimed at interfering with the activity of the Runx1 transcription factor and analysing consequences on Myl9a and Myl9b mRNAs expression (by another approach than using morpholinos). This information is given in response to reviewer 1's second point.

For the comment "time-lapse imaging should be performed on runx1 mutants to find out whether the patterns of Myl9b and F-actin are indeed perturbed in hemogenic endothelium in the mutant fish":

To perform a pattern analysis at a good resolution, we need to use ideally our 2D-map treatment of images, which we cannot perform presently because, as we mention in the text of our paper, we do not have enough sensitivity with our fish lines, neither for Myl9a, nor for Myl9b. The experiments requested by the Reviewer are extremely difficult experiment to perform (in particular in the 2-3 months of a revision) owing to low sensitivity (in particular for Myl9a and b) and variability (in particular when imaging stochastic processes, as EHT is). Hence, this type of experiments would need, at least, to have at hand a well-characterized stable fish line mutant for Runx1, which we presently do not have. This would indeed require such a line because, for Myl9b (and so would be the case for Myl9a), we would have to inject a Myl9b encoding plasmid (to increase the chance to have enough sensitivity of detection but having to face the problem of mosaicism in transient transgenesis). We currently do not handle transient transgenesis for expression of Lifeact and we can anticipate on the same type of difficulties.

So, we feel that we are not so far from addressing the reviewer's request (although rather indirectly) by showing the alteration of the F-actin pattern after the injection of the sih morpholino (see the new Figure 6, bottom of panel B), given that the blood flow controls the expression of Runx1.

> 2\) The authors showed that during the EHT, ZO1 and F-actin tend to be enriched in the trijunctions and membrane interfaces that are perpendicular to the blood flow, raising the possibility that blood flow may act as an extracellular mechanical force that triggers or affects the morphological change and cytoskeleton dynamics of HE during EHT. Thus, it would be of great interest to investigate the influence of blood flow on EHT dynamics by manipulating the physical property of blood flow (velocity, volume and viscosity, for example).

We have performed experiments using a silent heart morpholino and show/illustrate a series of results that are listed below. It should be emphasized that lack of blood flow triggered a quite significant decrease in the diameter of the aorta and distortions of its wall rendering the imaging more difficult than in normal conditions. However, we have been able to obtain few time-lapse sequences with interesting results regarding the orientation of the emergence and the morphodynamics of emerging cells (see below). We also explored further the phenotype, in particular with our 2D-algorithm to analyse the localization/organization of F-actin and ZO1. Impairing blood flow also dramatically affected the results of image treatment with the 2D-algorithm because these distortions project the signals outside from the crown drawn on aortic sections and supposed to contain signals of highest intensities (which are the signals projected on the 2D plane). Hence, we have narrowed down the images obtained by 2D-mapping to the plane of the aortic floor (that was less distorted than the aortic roof that flattened a lot, see Figure 6A) and obtained interesting information on the organization of F-actin (see below).

We also investigated the consequence of impairing blood flow on the localization/organization of ZO1. Unfortunately, fluorescence signals were too low and aorta too distorted to perform 2D-mapping (in addition, we wish to inform the reviewer that we had a serious incident in our animal facility and lost several of our fish lines, including the UAS:eGFP-ZO1 line that had been highly selected over several generations to reduce mosaicism that was very strong in the dorsal aorta. Hence, the experiments that were performed here with the sih morpholino were on transient expression, which is why we had very little amounts of cells expressing eGFP-ZO1 in the aortic floor (see new Figure 6, panel C)). However, although we were not able to perform 2D-mapping with our Z-stacks obtained with fishes transiently expressing eGFPZO1, 3D-projections and 3D-analysis with the Imaris software were very helpful and revealed alterations of eGFP-ZO1 localization in cells of the hemogenic endothelium, with altered recruitment at the sub-plasmalemmal level and apparent increase of the cytoplasmic pool. In addition to the morphological alterations of the dorsal aorta, we show/illustrate: (a) the absence, on the ventral side of the dorsal aorta, of EHT cells with their luminal/apical membrane oriented towards the sub-aortic space (in the same direction than the basal membrane) but, rather, the presence of ovoid cells (with the luminal/apical membrane protruding into the aorta lumen). 14 embryos were imaged all along the dorsal aorta at 48 hpf and 3 additional ones were used for time lapse sequences that lasted for 6 to 12 hours; in none of these embryos did we see any cup shaped EHT undergoing cells; (b) the emergence of ovoid cells in the lumen of the aorta (which we never saw before); (c) the clear modification in the organization of both F-actin and ZO1 in hemogenic and EHT cells. (d) the maintenance of mitosis of cells embedded in the aortic floor (most probably in the hemogenic endothelium). (e) evidence for the death of some of the cells that have emerged in the sub-aortic space (in the time window of our time-lapse experiments).

In addition, we also interfered with the heart beating by using treatment with tricaine. In these conditions, the inward bending of the apical/luminal membrane is abrogated and cells performing the emergence towards the sub-aortic space maintained the direction of the emergence towards the sub-aortic space (we introduced that information in the text as Data not shown).

Overall, these results show that hemodynamic forces contribute to the bending of the apical/luminal membrane of EHT cells towards the sub-aortic space (the cupshaped cells) as well as the direction of the emergence (the sub-aortic space) and reinforce the peculiarity of the EHT biomechanics, influenced by -- and adapted to -- the mechanical tensions exerted by the blood flow (Abstract).

These new results are included in a new figure, Figure 6, and 3 new Movies (Figure 6---video 1 (which is not a movie sensu stricto but a series of Z stacks illustrating the aortic morphology, intra-aortic cells, and the presence of ovoid cells included in the aortic floor), Figure 6---video 2 (illustrating the dynamics of the EHT emergence without flow) and Figure 6---video 3 (illustrating, by 3D-projections and 3D-analysis with the Imaris software, the alterations of eGFP-ZO1 localization in cells of the hemogenic endothelium). These results are contained in subsection "Hemodynamic forces control the topology and the dynamics of the emergence" and led to some modifications of the text on the sequential steps of the EHT (see subsection "EHT sequential steps and key features").
